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Cell therapy is a growing field as many diseases are still untreatable. Different types 
of cells may be used as part of a treatment for a variety of diseases and conditions.  As 
research advances, various cell types will be developed into treatments as novel cell 
therapies and studied for potential applications. Potential applications of cell therapies 
include treating cancers, autoimmune disease, urinary problems, and infectious disease, 
rebuilding damaged cartilage in joints, repairing spinal cord injuries, improving a 
weakened immune system, and helping patients with neurological disorders(1). 
Numerous clinical trials have recently focused on the use of mesenchymal stromal 
cells (MSCs) as a cell therapy for various diseases with unmet medical challenges, 
including graft-vs-host disease, osteoarthritis, autism, and auto-immune diseases. MSCs 
are multipotent cells that have both regenerative and immunomodulatory capacity, and 
which are being developed for therapeutic intervention across a variety of inflammatory 
and immune conditions(2, 3). MSCs can be isolated from various sources, such as bone 
marrow, umbilical cord, adipose tissue and bone marrow aspirate concentrate (BMAC), 
which introduces tissue dependent variability between MSC-based cell products that also 
differ according to donor. Furthermore, manufacturing processes vary between sites (both 
clinical and commercial), leading to process-dependent variability. These sources of 
variability across the MSC field compound the ability to compare clinical trial results and 
have contributed to a lack of conclusive historical data to support the potential for clinical 
efficacy(4). Overall, there is an obvious need for deep phenotypic characterization of 
MSCs to compare heterogeneity as a function of tissue-of-origin as well as donor, and to 
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identify potential phenotypic signatures that can be used for biomarkers or quality 
attributes for MSC-based cell products. 
My research focused on the study of MSCs as well as BMACs. BMACs contain 
small amounts of MSC but are still used in cell therapy as a MSC source. This study aims 
to assess the quality and gene expression profile of diverse cell preparation methods 
currently used in cell therapy, the transcriptional variability due to the tissue of origin of 
the cells used, and the pathways by which these cells modulate the immune system. I also 
evaluate the gene expression profiles of BMAC cell types from osteoarthritic (OA) patients 
and non-OA donors.  
Recently, single-cell RNA sequencing (scRNA-seq) has emerged as one of the next 
generation cell characterization techniques that can be used to gain deeper insight into gene 
transcriptional signatures at the single-cell level(5, 6). scRNA-seq enables the examination 
of genomes or transcriptomes of individual cells, providing a high-resolution view of cell-
to-cell variation or heterogeneity within a population. Moreover, this technique can be used 
to explore the distinct biology of individual cells and to understand temporal cellular 
processes and functions, such as differentiation, proliferation, and immune response 
potential(7). 
Research advance 1: Chapter 2 characterizes the gene expression profiles of bone 
marrow and umbilical cord tissue-derived MSC. I assess the variability due to tissue of 
origin, batch effects, and donor effects. Samples derived from the same tissue separate in 
two major groups corresponding to high quality cells and low-quality cells. The high-
quality cells further sub-divide in two subgroups referred to as high_a and high_b. Cells 
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from each donor belong to one or the other of these subgroups. The high-a cells are active 
cells expressing immunosuppressive genes, while high_b cells overexpress cell cycle 
genes, suggesting high_b cells may be more actively undergoing mitosis. The samples from 
the two different tissues also express qualitatively different gene expression profiles. 
Research advance 2: Chapter 3 describes how MSC immunosuppressive capacities 
are enhanced at the transcriptional level by proinflammatory cytokines. I characterize the 
gene expression profiles of bone marrow derived MSC exposed to TNF⍺ and IFN𝛾, 
showing that the MSC activated with IFN𝛾 express higher levels of immunosuppressive 
genes. Additionally, RNAseq analysis performed on T cells exposed to IFN𝛾-enhanced 
MSC reveals enrichment in gene activity related to T cell suppression and cell stress related 
pathways.   
Research advance 3: Osteoarthritis (OA) is a common degenerative disease, with no lasting 
cure. Even though it is considered a non-inflammatory disease, the immune system plays 
an important role in OA progression. The constant activation of pro-inflammatory 
cytokines due to tissue damage provokes deterioration of the cartilage. Cell therapy has 
been proposed as a treatment for this disease. MSC from different tissues of origin are 
being used to treat OA, such as commercial bone marrow derived MSC, bone marrow 
aspirates concentrate (BMAC) or autologous bone marrow derived MSC.  Chapter 4 
describes my characterization of the transcriptomic profiles of BMAC from OA patients 
and healthy donors. The results suggest overexpression of immune related pathways in 
BMAC samples from OA patients compared to samples from non-OA donors. Since pro-
inflammatory cytokines play a role in progression of the disease, this study suggests the 
study of allogeneic BMAC from non-OA patients as possible option for OA therapy.  
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CHAPTER 1. INTRODUCTION 
1.1. Immune system  
The function of the immune system is to prevent or limit infection. The immune 
system can distinguish between healthy cells and unhealthy (damaged or dying) cells by 
recognizing danger-associated molecular patterns (DAMPs) present on the surface of 
unhealthy cells(8). Cells may be unhealthy because of infection or because of cellular 
damage caused by non-infectious agents like cancer. Infectious microbes such as viruses 
and bacteria release another set of signals recognized by the immune system called 
pathogen-associated molecular patterns (PAMPs)(8). These signals activate the immune 
system. Lack of activation results in the spread of the infection. On the other hand, when 
the immune system is activated when there is no need or is not turned off after the danger 
has passed, different problems arise, such as allergic reactions and autoimmune disease. 
The immune system is complex, engaging numerous cell types that either circulate 
throughout the body or reside in a particular tissue. Each cell type plays a unique role, with 
different ways of recognizing problems, communicating with other cells, and performing 
specific functions. By understanding all the details behind this network, researchers may 
optimize immune responses to confront specific issues, ranging from infections to cancer. 
The immune system can be broadly sorted into two arms: innate immunity and 
adaptive immunity. Innate immunity is the immune system we're born with. It consists of 
barriers and non-specific responses on and within the body that keep pathogens out. 
Components of the innate immune system include skin, mucus, stomach acid, enzymes 
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from tears and skin oils and the cough reflex(9). There are also chemical components of 
innate immunity, including substances called interferons and interleukins, and broad-
specificity antimicrobial molecules(9). The adaptive, or acquired, immune system by 
contrast targets specific pathogens. Adaptive immunity is more complex than innate 
immunity. In this case, the pathogen must be processed and recognized by the body, and 
then the immune system creates antibodies specifically designed to target the pathogen(10). 
After the first exposure to the pathogen, the adaptive immune system remembers it, which 
allows for a more efficient response to the same pathogen in the future. In order to 
understand the immune system function and related diseases, it is critical to know the 
different components and their role within the immune system. 
1.1.1. Major components of the immune system 
All immune cells originate in the bone marrow and most of them develop into 
mature cells in the bone marrow. Some cell types, such as T cells, move out of the bone 
marrow to the thymus to complete their maturation process(11). 
Skin: The skin is the first line of defence against microbes. Skin cells synthesize 
and secrete antimicrobial proteins. 
Bone marrow: The bone marrow contains stems cells that can develop into a variety 
of cell types. Innate immune cells such as neutrophils, eosinophils, basophils, monocytes, 
dendritic cells, and macrophages come from myeloid stem cells present in the bone 
marrow. They are the first responders in case of infection. Mature myeloid and lymphoid 
immune cells are collectively called leukocytes. The adaptive immune cells, B cells and T 
cells, derive from lymphoid stem cells. These cells are responsible for specific responses 
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to microbes based on previous encounters. B cells make antibodies that attack bacteria and 
toxins, while T cells help destroy infected or cancerous cells. Killer T cells are a subgroup 
of T cells that kill cells that are infected or damaged. Helper T cells help determine which 
immune responses the body makes to a particular pathogen. Natural killer (NK) cells also 
derived from lymphoid progenitors and share features of both innate and adaptive immune 
cells: they provide immediate defences like innate cells, but also may be retained as 
memory cells like adaptive cells. B, T, and NK cells also are called lymphocytes. 
Bloodstream: Immune cells constantly circulate throughout the bloodstream, 
patrolling for problems. When blood tests are used to monitor white blood cells, another 
term for immune cells, a snapshot of the immune system is taken. If a cell type is either 
scarce or overabundant in the bloodstream, this may indicate an immune problem. 
Thymus: T cells mature in the thymus, a small organ located in the upper chest. In 
children, it supports negative selection against potentially self-reactive T-cells and thus 
prevents autoimmunity.  The thymus shrinks in size in adults but is still used for positive 
selection of T-cells that recognize foreign cells.  
Lymphatic system: The lymphatic system is a network of vessels and tissues 
composed of lymph, an extracellular fluid, and lymphoid organs, such as lymph nodes. The 
lymphatic system is a conduit for travel and communication between tissues and the 
bloodstream. Immune cells are carried through the lymphatic system and converge in 
lymph nodes, which are found throughout the body. 
Lymph nodes: These are structures that produce and store cells that fight infections 
and disease. If the adaptive immune cells in the lymph node recognize pathogens brought 
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in from a distant area, they will activate, replicate, and leave the lymph node to circulate 
and address the pathogen. B-cells usually mature in the germinal centers of the lymph node. 
Spleen: The spleen is an organ located behind the stomach and it is important for 
processing information coming from the bloodstream. Immune cells are enriched in 
specific areas of the spleen, and upon recognizing blood-borne pathogens, they will 
activate and respond accordingly. The spleen also helps control the amount of blood in the 
body and disposes of old or damaged oxygen-carrying red blood cells. 
Mucosal tissue: Mucosal surfaces, like the respiratory tract and gut, are prime entry 
points for pathogens. 
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Figure 1. Immune system organs. Causes of autoimmune diseases and their 
symptoms. Figure published on the NIH website, 2020 
(https://www.niehs.nih.gov/health/topics/conditions/autoimmune/index.cfm) 
1.1.2. Immune related diseases 
The immune system plays a major role in a daily fight against all pathogens. 
Multiple diseases can derive from unbalanced immune regulation. Disorders of the immune 
system can result in autoimmune diseases, inflammatory diseases and cancer, all reasons 
why its regulation is so important. Some of these diseases are due to the overreaction of 
the immune system, while other diseases occur for lack of response of the immune system, 
when facing a pathogen.  
Autoimmunity results from a hyperactive immune system, mistaking normal tissues 
as if they were foreign. In common diseases such as asthma and allergies a harmless 
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material, like pollen, food or mould, is mistaken for a severe threat which activates the 
immune system. More severe autoimmune diseases include Hashimoto's thyroiditis, 
rheumatoid arthritis, diabetes mellitus type 1 and systemic lupus erythematosus. 
According to the National Institute of Health (NIH), more than 24 million people 
in the United States suffer from autoimmune diseases(12). An additional eight million 
people have auto-antibodies, blood molecules that indicate a person’s chance of developing 
autoimmune disease(13). These diseases are affecting an ever-increasing proportion of 
people for reasons unknown. Likewise, the causes of these diseases remain a mystery. 
Studies indicate these diseases likely result from interactions between genetic and 
environmental factors. Gender, race, and ethnicity characteristics are all linked to a 
likelihood of developing an autoimmune disease(13).  
Immunodeficiencies, on the other hand, occur when the immune system is not 
strong enough, resulting in life-threatening infections.  In humans, immunodeficiency can 
either be the result of a genetic disease such as severe combined immunodeficiency, or a 
process of immunosuppression, sometimes drug-induced(14). 
Graft-versus-host disease (GVHD), is another immunological disorder that affects 
many organ systems, including the gastrointestinal tract, liver, skin, and lungs(15). GVHD 
is observed in 50% or more of patients receiving an organ transplant, including 
hematopoietic stem cell therapy. Since the graft contains T cells, there is a chance that the 
recipient expresses tissue antigens that are also present in the donor, as a consequence of 
which, the patient is incapable of mounting an effective response to eliminate the T 
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cells(16). Patients with a compromise immune system who receive white blood cells from 
another individual are at particularly high risk for this disease. 
The donor T cells respond to human leucocyte antigens (HLAs) on recipient 
cells(17). HLAs, which are highly polymorphic proteins, are encoded by the major 
histocompatibility complex (MHC). Class I HLA (A, B, and C) proteins are expressed on 
almost all cells of the body. Class II proteins (such as DR, DQ, and DP) are mainly 
expressed on leukocytes. Their expression can also be induced on other cell types after 
inflammation or injury. The acute GVHD is related to the degree of mismatch between 
HLA proteins from donor and patient(18). 
The disease results from a typical inflammatory process mediated by donor 
lymphocytes in the recipient. The immune system then attacks the cells displaying foreign 
HLA proteins, which in this case are self-cells. Levels of proinflammatory cytokines and 
chemokines increase, and the expression of key receptors on antigen-presenting cells 
(APCs) is stimulated, enhancing the presentation of the patient’s HLA proteins to the donor 
immune cells that mediate GVHD(19, 20).  Unchecked, GVHD can result in a sever and 
life-threatening autoimmune reaction to the organ transplant. 
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Figure 2. Pathophysiology of acute GVHD(15). 
IL-1=interleukin 1. IFN γ=interferon γ. LPS=lipopolysaccharide. Treg=regulatory T 
cell. Th1=T-helper 1 cell. CTL=cytotoxic T lymphocyte.  
1.1.3. Diagnosis and treatment of immune related diseases 
More than 80 autoimmune diseases are known. Some of them are well known, such 
as type 1 diabetes, multiple sclerosis, lupus, and rheumatoid arthritis, while others are rare 
and difficult to diagnose. With rare autoimmune diseases, patients may suffer years before 
getting a diagnosis. Even though symptoms of immune diseases vary, fever and fatigue are 
common signs. Most of the time, immune deficiencies are diagnosed with blood tests that 
either measure the level of immune elements or their functional activity. Allergic 
conditions may be evaluated using either blood tests or skin allergy tests. 
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Most of these diseases have no cure. Some require lifelong treatment to ease 
symptoms. In autoimmune conditions, medications that reduce the immune response, such 
as corticosteroids, can be helpful.  
In a study published in Arthritis and Rheumatology(21), the researchers found that 
the prevalence of antinuclear antibodies (ANAs), the most common biomarkers of 
autoimmunity, is significantly increasing in the U.S. overall and particularly in certain 
groups. These groups include males, non-Hispanic whites, adults 50 years and older, and 
adolescents. The study is the first to evaluate ANA changes over time in a representative 
sampling of the U.S. population. The reasons for this increase in ANA are not clear, but 
they are concerning and may suggest a possible increase in autoimmune disease cases in 
the future.  
It is clear that we are far from completely understanding immune related diseases, 
which is why is so important not only to clarify the origin of these diseases but also to 
develop new strategies to treat or cure them.  
1.2. Osteoarthritis 
Osteoarthritis (OA) is a joint disorder involving cartilage, bone and synovial 
membrane. It can affect both small joints, such as toe and finger joints, as well as the large 
joints of the hip and knee(22). Globally, prevalence varies depending on the population 
genetics and environment, going from 17% to 47%(23, 24) . According to the Center for 
Disease Control and Prevention (CDC) OA affects over 32.5 million adults in the US(25). 
Its progress is usually slow; the pain and restricted function usually appears in people over 
40 years old, and its prevalence rises with age. 
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Initially, osteoarthritis has been considered to be a disease of the articular cartilage, 
but recent research has indicated that the condition involves the entire joint(26-28). OA is 
classed as a degenerative disease due to the joint deterioration over time. The loss of 
articular cartilage is thought to be the primary change, but this is followed by a combination 
of cellular and biomechanical changes, including subchondral bone remodeling, formation 
of osteophytes (bone spurs), the development of bone marrow lesions, and meniscal 
damage, among other pathologies(29-32) (Figure 1.3). OA is considered to be a non-
inflammatory condition even though inflammation is a symptom. 
 
Figure 3. Joint anatomy in healthy and osteoarthritic patient, copied from 
https://orthoinfo.aaos.org/en/diseases--conditions/arthritis-of-the-knee, accessed Dec 
20, 2020. 
1.2.1. Diagnosis of OA 
OA is diagnosed and graded by the degree of bone changes seen on an X-ray. The 
most commonly used X-ray tool to grade the severity of the disease is the Kellgren-
Lawrence (KL) scale. This ranges from a score of zero, where no change is seen, to a 
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maximum score of four. A maximum score means the changes in the joint are severe, 
showing a significant decrease in joint space and marked osteophyte deposition. 
1.2.2. Pathophysiology and risk factors 
The following joint tissues are affected in OA. 
Bone: In most people, bone changes in OA are seen much later in life, and the 
triggers are poorly understood. In some people, the composition of bone is affected by 
inherited disorders, which can lead to an onset of OA at an earlier age(22). The bone just 
beneath the cartilage in the synovial joint is known as subchondral bone and has a number 
of different zones. The upper zone, called the subchondral bone plate, is composed of 
relatively non-porous bone with a limited blood supply. Beneath this is a spongier layer of 
bone called cancellous or trabecular bone.  In a healthy person, the bone is constantly 
modified by modelling and resorption. This allows it to repair and adapt to mechanical 
changes. In OA patients, the subchondral bone plate thickens, and osteophytes are formed 
at the joint margins. It is not yet clear whether changes within subchondral bone precede 
changes in the articular cartilage or whether they accompany disease progression. 
However, the two processes are closely related(33). MRI studies have demonstrated that 
these bone lesions themselves are associated with development and worsening of cartilage 
loss(34). 
Synovial membrane: It’s unclear whether the morphological changes that occur in 
the osteoarthritic synovial membrane are primary or whether they are the result of joint 
inflammation, cartilage degradation, and lesions of the subchondral bone(35). The synovial 
inflammation or synovitis is believed to be induced at first by the proteolytic degradation 
 12 
components of the cartilage matrix. These components are released into the synovial fluid 
and are phagocytosed by macrophages. This process leads to the synthesis of mediators 
contributing to synovial inflammation and degradation of the cartilage(36). Studies of the 
changes in the synovium that occur at various stages of osteoarthritis have found that the 
amount of fibrin deposited in the synovial membrane and the degree of leukocyte 
infiltration are correlated with disease severity(37). High levels of osteopontin, a protein 
synthesize by various tissues like bone marrow cells and macrophages, has been correlated 
with disease severity(38).  
Cartilage: Normal adult cartilage is formed by extracellular matrix (water, collagen, 
proteoglycans and a very small component of calcium salt) and chondrocytes(38). Pressure 
on cartilage causes the cartilage cells (chondrocytes) to produce a collagen and protein 
matrix. Replacement of the matrix is normally a slow process, but excessive loading, like 
obesity or genetic polymorphisms, can lead to activation of enzymes (metalloproteases) 
that digest it, leading to thinning and damage(39). Osteoarthritis result from failure of 
chondrocytes to maintain homeostasis between synthesis and degradation of these 
extracellular matrix components(40). It is not known what initiates the imbalance between 
degradation and repair of cartilage. The inflammation causes an increase in enzymatic 
activity that may allow the formation of “wear” particles, which could be engulfed by 
resident macrophages(33). When the production of these “wear” particles overwhelm the 
capacity of the immune system to eliminate them, they become mediators of inflammation, 
stimulating the chondrocyte to release degradative enzymes. This starts a cascade of actions 
that lead to the release of proinflammatory cytokines, like TNFα, IL-1 and IL-6. These 
cytokines will activate the chondrocytes which will lead to the secretion of 
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metalloproteinases and inhibition of type II collagen production, increasing cartilage 
degradation(41). 
Inflammation: Once cartilage has been damaged, the products of that damage are 
engulfed and digested by synovial cells. This leads to the production of inflammatory 
mediators, such as pro-inflammatory cytokines interleukin IL-1, IL-6 and IL-8, tumour 
necrosis factor and prostaglandin PGE2.  
The degree of inflammation is a key difference between OA and rheumatoid arthritis. OA 
is not always recognized as an inflammatory disease because there are often low levels of 
leukocytes in the synovial fluid, one of the parameters used to identify an inflammatory 
condition. Inflammation in OA is usually restricted to a specific area of a joint, but can 
sometimes be so pronounced that inflammatory chemicals are seen in the circulation as 
well as the synovial fluid. The degree of inflammation is associated with disease severity 
and pain.  
Meniscus: Meniscal degeneration is commonly seen in osteoarthritis, where the 
meniscus appears torn, fragmented or completely destroyed(42). Degeneration of the 
meniscus initiates from within the tissue. Type I collagen content decreases gradually from 
the surface zone to the middle and the deep zone of osteoarthritic meniscus(43). Levels of 
proteoglycan also increase in osteoarthritic meniscus when compared to normal 
meniscus(43). All these intrameniscal changes correlate with peri-meniscal synovitis, and 
calcification (which is not limited to the outer, peripheral portion of the menisci(44, 45)) 
further contributes to meniscal degeneration and reduced meniscal strength. The meniscus 
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is then less able to stand loading and force transmission during normal movements of the 
joint, further leading to degenerative tears(46). 
 
Figure 4. Molecular mechanism of osteoarthritis. Image published by 
Bhattacharyya et al. 2003(47). 
1.2.3. Treatment 
Current treatments target the pain (Nonsteroidal anti-inflammatory drugs and 
Acetaminophen) or the mobility (Physical therapy). There are no pharmaceutical 
treatments that can reverse the disease, so attention is turning to research on the effect of 
cell therapy for osteoarthritic patients. As of December 2020, there are 206 clinical trials 
for osteoarthritis involving cell therapy. Multiple cells types have been used, including 
mesenchymal stromal cells and bone marrow aspirates. Mesenchymal stromal cells (MSC) 
are widely used in clinical trials(48-50). Some clinical trials have seen encouraging 
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outcomes when using bone marrow aspirates concentrate, which also contains MSC(47, 
51-54). 
The reproducibility of the results seen in previous research is still challenging. A 
wide variety of cells are used for this purpose, introducing donor, technical, and tissue-fo-
origin related variability. More studies need to be done to understand the mechanism by 
which these cells modulate the patient’s condition. 
1.3. Cell therapy 
Cell therapy (also called cell transplantation) is a therapy in which viable human cells 
are injected, grafted or implanted into a patient in order to provide a medicinal effect. For 
example, in the case of ischemic heart disease, transplantation of therapeutic cells can 
improve perfusion, improve heart function and ultimately improve quality of life for 
patients(55). With new technologies many different types of cells may be used as part of a 
treatment for a variety of diseases and conditions.  Some of the cells that may be used 
include hematopoietic stem cells (HSC), skeletal muscle stem cells, mesenchymal stromal 
cells, lymphocytes, dendritic cells, and cell aspirates (from bone marrow or stromal 
vascular fractions)(56). 
Cell therapy trials have shown promising results for multiple disease treatments. 
Clinicaltrials.gov lists more than 35,000 studies for cell therapy assessment. Some cells, 
like MSC, have been shown to have little or no undesirable effects, suggesting that they 
are generally a safe option for therapeutic purposes(48-50, 57, 58). However, quality 
control is essential both to maintain safety and promote uniform potential. The cells 
injected to the patients may come from the patient him- or herself (autologous) or from an 
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unrelated healthy donor (allogeneic). Either way the rejection rate is of these cells is 
extremely low with appropriate medical care.  
Numerous clinical trials with promising results have focused on the use of MSCs as 
a cell therapy for various diseases with unmet medical challenges, including graft-vs-host 
disease, osteoarthritis, autism, and auto-immune diseases(48-50, 57-60). 
MSCs are multipotent cells that have both regenerative and immunomodulatory 
capacity, and which are being developed for therapeutic intervention across a variety of 
inflammatory and immune conditions(2, 3). MSCs can be isolated from various tissues, 
such as bone marrow, umbilical cord, and adipose tissue, which introduces tissue 
dependent variability between MSC-based cell products that also differ according to donor. 
Furthermore, manufacturing processes vary between sites (both clinical and commercial), 
leading to process-dependent variability. These sources of variability across the MSC field 
compound the ability to compare clinical trial results and have contributed to a lack of 
conclusive historical data to support the potential for clinical efficacy(4). 
MSCs are typically identified based on the expression status of a panel of specific 
surface markers, their ability to adhere to plastic, and their tri-lineage differentiation 
potential to adipocytes, osteoblasts and chondroblasts, following recommendations of the 
International Society for Cell and Gene Therapy (ISCT)(61, 62). However, these minimal 
MSC identification and functional criteria, especially surface marker expression, often do 
not correlate with the regenerative or immunomodulatory functions of specific 
cultures(63). Moreover, the proportion of “stem” like cells that have high regenerative 
capability varies across MSC donors(64). Overall, there is an obvious need for deep 
 17 
phenotypic characterization of MSCs to compare heterogeneity as a function of tissue-of-
origin as well as donor, and to identify potential phenotypic signatures that can be used for 
biomarkers or quality attributes for MSC-based cell products. 
As research advances, various cell types will be developed into treatments as novel 
cell therapies and studied for potential applications. Potential applications of cell therapies 
include treating cancers, autoimmune disease, urinary problems, infectious disease, 
rebuilding damaged cartilage in joints, repairing spinal cord injuries, improving a 
weakened immune system, and helping patients with neurological disorders(1). Even 
though, MSCs are widely used for cell therapy, other cell types, like hematopoietic stem 
cells (HSCs), or group of cells, like bone marrow aspirate concentrate and stromal vascular 
fraction, are also used for medical purposes. 
1.4. Transcriptomics 
The aim of this study is to assess the variability in function of MSC from different 
origins and BMAC from OA patients and non-OA donors. In order to do this analysis, I 
decided to use transcriptomics.  
Transcriptomics is the study of the transcriptome, the complete set of RNA 
transcripts that are produced by the genome, in a specific cell, using high-throughput 
methods, such as microarray analysis, bulk RNA-seq and single cell RNA-seq.  
RNA-Seq may be used to identify genes within a genome and quantify the activity 
of the genes at a point in time. The read counts can be used to accurately model the relative 
gene expression level of each gene, and the comparison of transcriptomes allows the 
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identification of genes that are differentially expressed in distinct cell populations, or in 
response to different treatments. RNA-Seq also provides a more precise measurement of 
levels of transcripts and their isoforms compare to other methods such as microarray 
analysis(65). In general, the transcriptome analysis is of growing importance in 
understanding how altered expression of genetic variants contributes to complex diseases 
such as cancer, diabetes, and heart disease. Analysis of genome-wide differential RNA 
expression provides researchers with greater insights into biological pathways and 
molecular mechanisms that regulate cell fate, development, and disease progression. 
However, like any other approach, transcriptomics has its limitations. mRNA abundance 
is an unreliable indicator of protein activity(66) as the transcript quantitation can be 
affected by biases created during cDNA library construction and sequence alignment. 
Even though RNA-seq have limitations, it allows to understanding the 
transcriptome profile of different cells, which is essential for interpreting the functional 





CHAPTER 2. SINGLE CELL RNA-SEQ OF OUT OF 
THAW MESENCHYMAL STROMAL CELLS SHOWS 
STRIKING TISSUE OF ORIGIN DIFFERENCES AND 
INTER DONOR CELL CYCLE VARIATIONS  
2.1. Abstract 
 Mesenchymal stromal cells (MSCs) from a variety of tissue sources are widely 
investigated in clinical trials, and the MSCs are often administered immediately after 
thawing the cryopreserved product. While previous reports have examined the 
transcriptome of freshly cultured MSCs from some tissues, little is known about the single-
cell transcriptomic profiles of out-of-thaw MSCs from different tissue sources.  Such 
understanding could help determine which tissue origins and delivery methods are best 
suited for specific indications. Here, we characterized cryopreserved MSCs, immediately 
post-thaw, from bone marrow (BM) and cord tissue (CT), using single-cell RNA 
sequencing (scRNA-seq). We show that out-of-thaw BM- vs. CT-MSCs have significant 
differences in gene expression. Gene-set enrichment analyses implied divergent functional 
potential. In addition, we show that MSC-batches can vary significantly in cell cycle status, 
suggesting different proliferative vs. immunomodulatory potentials. Our results provide a 






Mesenchymal Stromal Cells (MSCs), often referred to as Mesenchymal Stem Cells 
or Signaling Cells, are cells isolated from various tissues that have shown multipotent, 
regenerative, and immunomodulatory capacities in vitro. These cells, from a variety of 
tissue-sources, are being evaluated for therapeutic interventions, especially across a variety 
of inflammatory and immune conditions(2, 3). Numerous clinical trials have focused on 
the use of MSCs as a cell therapy for various diseases with unmet medical challenges, 
including graft-vs-host disease, osteoarthritis, autism, acute respiratory distress syndrome 
(ARDS), autoimmune diseases, and even COVID-19. A ClinicalTrial.gov search (date: 
August 7, 2020) with the keyword: MSC as other terms shows 4,044 studies that are either 
recruiting, not yet recruiting, enrolling by invitation, and active but not recruiting. MSCs 
are also widely used in developing engineered tissues ex vivo(67-69). Several are also 
working on developing MSC-based therapies and others are developing reagents and large-
scale cell banks for eventual clinical use.  
Despite such widespread interest in academia, clinical trials, and in industry, the 
characteristics of MSCs that are most correlative to their specific in vivo function remain 
unknown. MSCs can be isolated from various tissues, such as bone marrow, umbilical cord, 
placental, and adipose tissue, which introduces tissue-dependent variability between MSC-
based cell products that may also differ according to donor.  Furthermore, manufacturing 
processes vary between sites (both clinical and commercial), leading to process-dependent 
variability.  These sources of variabilities across the MSC field confound the ability to 
compare clinical trial results and have contributed to a lack of conclusive historical data to 
support their potential for clinical use(4).  
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The International Society for Cell and Gene Therapy (ISCT) standards identify 
MSCs based on the expression status of a panel of specific surface markers, their ability to 
adhere to plastic, and their ex vivo tri-lineage differentiation potential to adipocytes, 
osteoblasts and chondroblasts(61, 62).  However, these minimal MSC identification and 
functional criteria, especially surface marker expression, often do not correlate with their 
regenerative or immunomodulatory functions(63). Moreover, the proportion of “stromal” 
like progenitor cells that have high regenerative capability varies across MSC donors(64).   
Therefore, there is an obvious need for deep phenotypic characterization of MSCs to 
compare heterogeneity as a function of tissue-of-origin as well as donor, and to identify 
potential phenotypic signatures that can be eventually used as predictive biomarkers or 
critical quality attributes (CQAs) for MSC-based products, and for understanding their 
putative Mechanisms of Action (MoAs).  
Recently, single-cell RNA sequencing (scRNA-seq) has emerged as one of the next 
generation cell characterization techniques that can be used to gain deeper insight into gene 
transcriptional signatures at the single-cell level(5, 6). scRNA-seq enables the examination 
of genomes or transcriptomes of individual cells, providing a high-resolution view of cell-
to-cell variation or heterogeneity within a population. Moreover, this technique can be used 
to explore the distinct biology of individual cells and to understand temporal cellular 
processes and functions, such as differentiation, proliferation, and immune response 
potential(7). scRNA-seq has been previously used to characterize hematopoietic 
differentiation(70-72) and immune cell subsets(73), including dendritic cells, 
monocytes(74), and innate lymphoid cells(75). A handful of reports have also used scRNA-
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seq to characterize differential gene expression in freshly-prepared MSCs from umbilical 
cord(76), adipose tissue(62), Wharton’s jelly(77) and bone marrow(78, 79). 
In many clinical trial settings for allogeneic MSC-based off-the-shelf cellular 
therapies, to circumvent logistical and manufacturing challenges, MSC products are used 
post-thaw (directly from a frozen vial), rather than fresh (without freezing after culture), or 
culture-rescued (re-cultured after thawing)(3, 80). Since out-of-thaw MSC products could 
have different metabolic and functional characteristics from their fresh counterparts(80), 
phenotypic and functional characterization directly on the out-of-thaw MSC product is 
necessary to be able to find correlative attributes between their in vitro cell characteristics 
and corresponding clinical or pre-clinical efficacy. A comprehensive characterization of 
out-of-thaw MSC product from different tissue sources and donors at single-cell level may 
provide information on potential critical quality attributes (CQAs) and Mechanisms of 
Action (MoA) of the cells, and can be used to select MSC donor and/or sources for disease 
specific cell therapies.  
In this study, we performed scRNA-seq using the drop-seq method(5, 81) to compare 
single-cell transcriptome profiles between commercially available bone marrow-derived 
MSCs (BM-MSCs) from six donors from RoosterBio Inc. (Frederick MD), and umbilical 
cord-tissue derived MSCs (UCT-MSCs) from four donors provided by Duke University. 
We characterized a total of 13 out-of-thaw samples from these ten MSC donors. 
Specifically, we assessed differences between individual donors as well as differences 
between MSC tissue sources. To overcome issues with zero counts that complicated 
differential expression analysis and to provide flexibility in normalization, we also 
 23 
introduce a new analytical framework, scPool, in which similar cells from the same donor 
are pooled into pseudo-cells. 
2.3. Results 
2.3.1. Donor Effects on Bone Marrow-Derived MSC Gene Expression 
A total of seven bone marrow-derived MSC (BM-MSC) samples from six donors 
were thawed and processed for scRNA-seq analysis (Tables 1 and 2). First, we compared 
two of the BM-MSC samples between pre-freeze and post-thaw conditions to understand 
freeze-thaw effects on MSC gene expression. Our analysis indicated a shift in the genetic 
profile between pre-freeze and post-thaw conditions (Figure S1). Pre-freeze samples 
showed significant overexpression of 1,743 genes relative to post-thaw samples at the 5% 
false discovery rate (FDR) threshold, while 310 genes were significantly overexpressed in 
the post-thaw samples compared to the pre-freeze samples. Some of the pathways 
overexpressed in the pre-freeze samples are cytokine signaling (FOS, MMP2, TLN1, 
FOSB), cell proliferation and cell adhesion (ZYX, ITGA5, CLIC1 etc.), while the pathways 
over-expressed in the frozen, post-thaw samples are carbohydrate interconversions 
(UGP2), cholesterol/Steroid biosynthesis and regulation of apoptosis (PSMA2, PSMB1). 
Having established that the freeze-thaw process imparts substantial changes in gene 
expression profiles of MSCs, we focused our analyses on post-thaw MSC products from 
BM and CT origins, since these are being widely used in numerous clinical trials.  
Table 1 summarizes the sample data for all BM samples. Samples BM1 and BM2a 
were processed in laboratory A, while samples BM2b, BM3, BM4, BM5 and BM6 were 
processed in laboratory B (Table 1). An average of 305 cells were profiled per sample, with 
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an average read depth of 29,703, representing 12,348 UMI (Unique Molecular Identifier) 
and 3,836 expressed genes per cell (Table 1). The profiles were clustered with both 
Seurat(82) and SC3 pipelines(83).  Since the latter is optimized for relatively small 
experimental designs, we present the results of SC3, but note that similar findings were 
obtained with Seurat (Figure S2). Before characterizing differential expression among 
samples, we confirmed that the MSC-identity markers established by the ISCT, namely 
NT5E (CD73), THY1 (CD90) and ENG (CD105) were detected in the majority of cells in 
the bone marrow and umbilical cord tissue derived MSCs (Figure S3). Furthermore, CD34, 
CD14, CD19 and PECAM1 - all markers of hematopoietic or lymphoid lineages, were 
absent.  
Table 1. Number of cells, average number of genes and average number of UMI per 
cell per BM-MSC sample. 
Samples 




















A 293 29,671,530 15,469 2,218 293 Male 25 2,693 7,581 
BM2a 
A 310 29,943,109 46,467 3,855 252 Male 21 3,714 12,242 
BM2b 
B 199 41,511,093 39,417 4,686 199 Male  21 4,395 15,506 
BM3 
B 590 35,842,779 26,580 4,272 452 Male 22 4,193 13,415 
BM4 
B 557 25,262,984 17,668 3,803 542 Female 26 3,430 9,718 
BM5 








Projecting each cell against the first two Principal Components (PC) of gene 
expression, three clusters of single cell profiles were observed (Figure 5A).  PC1 is highly 
negatively correlated with the total UMI count per cell. Accordingly, the smallest cluster 
located to the right, consists of 17% of the cells all of which had low UMI counts, typically 
fewer than 1,000 detected genes, and low ribosomal protein transcript counts (Figure 5B).  
These low UMI counts cells were more prevalent in two donors studied - one from each of 
the two laboratories (Lab A and Lab B; BM1 and BM4, respectively: Figure 5C), 
suggesting the low UMI count may not be related to the lab in which they were 
manufactured.  It is not clear whether the unusual profile of these cells is a technical 
artefact, or has a biological basis, but they appear to be of low quality and were excluded 
from all subsequent analyses. 
(A) The first two Principal Components of gene expression identify two broad clusters of 
cells, which are colored by sample: Cluster BM-Low, which correspond low UMI count 
cells and cluster BM-High, with high UMI count cells. (B) Violin plots show the density of 
the number of Genes, UMI, and Ribosomal Protein transcripts (RP) per cell.  (C) 






















































































































Figure 5. Clusters of BM-MSC transcriptome profile. 
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of cells in the indicated sample, and the color of each box corresponds to cells in cluster 
BM-Low (blue), BM-High a (red) or BM-High b (green).   (D)  Within cluster High, SC3 
identifies two clusters of cells, which separate along PC3 as indicated by the red and blue 
points.  (E)  Shading of cells by sample confirms that cells from each donor belong to one 
of the two sub-clusters, although with subtle separation associated with PC3. 
Two clusters identified by SC3 in the remaining high-quality datasets largely 
differentiate along PC3 (Figure 5D).  Three of the five samples expanded in laboratory B 
(BM3, BM4 and BM6) were predominantly found in cluster BM-High_b; the other two 
samples along with both of the samples expanded in laboratory A (BM1, BM2a, BM2b 
and BM5) were predominantly found in cluster BM-High_a (Figure 5E).  Both samples 
from the donor whose cells were cultured in each of the laboratories are in cluster BM-
High a (BM2a and BM2b), suggesting that the difference is more likely to be donor-related 
than due to a laboratory or technical effect.  Nevertheless, Figure 5E shows that even 
between the two laboratories, the cells from this donor tend to separate along PC3.   
2.3.2. Single Cell Pooling Enhances Differential Expression Analysis for 
Bone Marrow-MSC samples 
Although the above analysis follows current standard practice, it is nevertheless 
subject to the caveat that for a large percentage of the genes, transcripts are only observed 
in fewer than half of the cells, and consequently the differential expression analysis is 
mostly based on presence-versus-absence. In order to lend robustness to the conclusions, 
we elected to analyze differential expression with an alternative strategy that accounts for 
the impact of a high proportion of drop-outs in scRNA-seq.  Our method, “scPool”, is based 
on pooling of cells of the same type within samples, which ensures that a high proportion 
of genes are represented by an approximately normal count distribution.  It also allows for 
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fitting of normalization strategies initially developed for bulk microarray or RNA-seq 
analysis. 
After normalizing gene expression values to counts per 10,000 UMI, differential 
expression analysis between clusters BM-High_a and BM- High_b was performed in 
EdgeR with donor as a random covariate, yielding 4,624 genes at a FDR of 5%.  There 
were 2,230 genes upregulated in cluster 2a, and 2,394 upregulated in cluster 2b (Figure 
6A).  Gene ontology analysis detected strong enrichment for multiple pathways involved 
in cell cycle regulation in cluster BM-High_b (Figure 6B).  By contrast, cluster BM-High_a 
showed upregulation of multiple pathways related to immune signaling and other processes 
expected to be characteristic of functional MSCs (Figure 6B). On the basis of the cell cycle 
gene expression, cells in cluster BM-High_b may be preparing for or undergoing cell cycle 
division, whereas the cluster BM-High_a MSCs may be more likely to be in G0 phase. 
Alternately the two populations may simply express cell cycle related genes at different 
levels, without this reflecting cell cycle stages.  
To implement the scPool strategy, we created random pools of pseudo-cells 
consisting of the sum of raw read counts for random draws of 20 cells (excluding the low-
quality cluster 1 cells) within a donor’s sample.  The number of such pseudo cells ranged 
from 6 for sample BM5 to 20 for sample BM4.  We then retained all genes with at least 
one read in 90% of the pseudo cells, a total of 6,422 genes.  This dataset was normalized 
using the supervised normalization of microarrays (SNM) protocol(83) with cluster sub-
type as the biological variable, adjusting for donor effects, and analysis of variance was 
used to detect differentially expressed genes.  The procedure was repeated ten times, and 
the fold change and p-values were averaged to generate a robust list of cluster-specific 
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genes. Compared with the single cell analysis, 1,290 more significant differentially 
expressed genes were detected.  The single cell analysis was done using the Wilcoxon rank 
sum test for the differentially expressed genes and a threshold lower than 0.05 for the 
adjusted Pvalue. Figure 6C shows generally higher significance than the single cell-level 
analysis, without over-estimation of fold-changes for a large fraction of the less-significant 
genes.   
(A)  Volcano plot of negative log P-value (NLP) against fold change, created with standard 
single cell level computation in edgeR.  (B)  Corresponding volcano plot based on the 
pseudo pools results.  Blue shading indicates cell cycle markers obtained from 
cycleBase(84). (C)  Chord diagram of gene ontology analysis highlighting the top 10 
differentially expressed genes in each of 8 pathways representative of the up- and down-
regulated genes.  Ribbons link genes on the left to pathways on the right; genes associated 
with multiple pathways bifurcate.  Note that in this depiction, the direction of differential 
expression is the same for all genes in the pathway. 
Next, we probed the magnitude of donor contributions to variance within clusters, 






















Figure 6. Differential expression between the two High clusters of Bone Marrow-
MSC samples. 
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the high-quality cluster BM-High_a cells, donor effects accounted for 8.5% of the variance.  
A similar result was observed for cluster BM-High_b. 
2.3.3. Donor Effects on Umbilical Cord Tissue Derived MSC Gene 
Expression 
Umbilical cord tissue derived MSC (UCT-MSC) samples from four donors were 
used for scRNA-seq analyses.  A total of six scRNA-seq samples were prepared, all from 
the same lab, including three biological replicates of one donor sample (UCT1a, UCT1b 
and UCT1c).  An average of 349 cells were profiled per sample, with an average read depth 
of 27,417, representing 9,700 UMI and 3,057 expressed genes per cell (Table 2).  The 
UCT-MSC gene expression profiles were also analyzed with the SC3 pipeline.  
Table 2. Number of cells, average number of genes and average number of UMI per 
cell per UCT-MSC sample. 
Samples 


















nUMI per cell 
UCT1a 
C 161 16,255,153 19,563 2,472 161 Male -- 2,808 8,458 
UCT1b 
C 251 31,333,645 38,809 3,840 251 Male -- 3,667 12,075 
UCT1c 
C 251 31,333,645 38,809 3,840 251 Male -- 2,477 7,321 
UCT2 
C 692 59,783,150 25,248 2,979 547 Male -- 3,053 9,381 
UCT3 
C 397 43,757,708 26,241 2,724 396 Male -- 2,720 9,262 
UCT4 
C 284 20,167,531 29,162 3,717 259 Male -- 3,616 11,711 
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Two major clusters of single cell profiles were again observed in the projection of the first 
two principal components of the UCT-MSC data (Figure 7A).   
(A) The first two Principal Components of gene expression identify the two major clusters 
of cells, which are colored by sample.  Most cells of each sample cluster together. (B) 
Violin plots show the density of the number of Genes, UMI, and Ribosomal Protein 
transcripts (RP) per cell.  (C) Association of cells with clusters.  The width of each column 
is proportional to the number of cells in the indicated sample, and the color of each box 
corresponds to cells in cluster 1 (blue), 2a (red) or 2b (green). 
The smallest of these, consisting of 13% of the cells, was characterized by cells 
with low UMI counts, typically fewer than 2,000 detected genes (Figure 7B), similar to the 
BM-MCS analysis.  These low UMI-count cells were present in every sample but again 
were more prevalent in two of the samples (UCT1c and UCT3: Figure 7C). It is not clear 
whether the origin of these cells is a technical artefact, or has a biological basis, but they 
also appear to be of low quality and were again excluded from all subsequent analyses.  
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Figure 7. Clusters of UCT-MSC Profiles. 
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(UCT2 and UCT3) and UCT-High_b (UCT1a, UCT1b, UCT1c and UCT4), though in this 
case they did not clearly correspond to one of the Principal Components. The three 
replicates of donor UCT1 were primarily captured within the UCT-High_b cluster, 
suggesting consistency of technique. 
Implementation of the scPool strategy for detecting differential gene expression 
between the two UCT-MSC clusters, after removing the low-quality cells, detected 2,526 
genes at an FDR of 5%. Directional up-regulation of established marker genes for mitosis 
is evident in cluster UCT-High_b as indicated by blue points in the volcano plot Figure 
8A. Gene ontology analysis (Figure 8B) indicates enrichment for up-regulation of collagen 
biosynthesis, integrin signaling, extracellular matrix (ECM) organization, and protein 
translation pathways in the cluster UCT-High_a MSCs, whereas the cluster UCT-High_b 
cells are enriched for cell cycle regulation, degradation of mitotic proteins, as well as 
various processes related to cell cycle progression, including CDC20 mediated degradation 
of Securin, and auto degradation of CDH1, suggesting potential donor-dependent 
heterogeneity in the gene expression profile of UCT-MSC. 
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Figure 8. Differential expression between two high quality UCT-MSC clusters. 
(A) Volcano plot of significance against fold difference in gene expression for the 
comparison of clusters 2a and 2b.  Blue points indicate genes with established roles in cell-
cycle regulation. (B) Chord diagram of gene ontology analysis highlighting the top 10 
differentially expressed genes in each of 10 pathways representative of the up- and down-
regulated genes.  Ribbons link genes on the left to pathways on the right; genes associated 
with multiple pathways bifurcate. 
2.3.4. Comparison between Bone-Marrow and Cord-Tissue derived MSC 
single-cell gene expression profiles 
Direct comparison of MSCs derived from bone marrow and MSCs from umbilical 
cord tissue was performed by combining the analyses of the previous two datasets. As 
expected, Principal Component Analysis (PCA) of the raw single cell profiles again 
identified two major clusters of low and high UMI-abundance cells along PC1, but in this 
case PC2 of the joint analysis cleanly differentiates the BM and CT samples (Figure 9A). 
This result implies that there are significant differences in gene profile between MSCs 




































Volcano plot Cluster 2a − Cluster 2b











Figure 9. Differential expression analysis between high quality BM-MSC and UCT-
MSC. 
(A) Principal component analysis showing clustering of MSC samples by tissue of origin 
(bone marrow vs umbilical cord tissue). (B) Chord diagram summarizing differential 
expression between UCT-MSC and BM-MSC.    (C) Cluster-specific pathway expression 
is not conserved between the two High clusters from the two tissues of MSC origin. Chord 
diagram contrasting clusters BM-High a versus UCT-High a. 
We implemented scPool to identify differentially expressed genes between MSCs 
derived from the two sources, after removing the low-quality cells identified in our first 
series of analysis.  Pools of 20 cells were again assembled computationally within donor 
and mixed model analysis of variance was performed, with donor as a random effect.  3,437 
genes were found to be up-regulated in the BM-MSC, and 3,250 genes down-regulated, 




S4). Gene ontology analysis of all the significantly differential expressed genes indicates 
enrichment for metabolism of lipids and lipoproteins, cholesterol biosynthesis, 
mitochondrial translation, and metabolic pathways in the BM-MSCs, whereas the UCT- 
MSCs were enriched for ECM organization, collagen biosynthesis and signal transduction 
(Figure 9B). UCT-MSC also showed relative up-regulation of mitotic cell cycle pathways, 
but this likely reflects the greater ratio of UCT-High_b to UCT-High_a cluster cells than 
of BM-High_b to BM-High_a cells, rather than a consistent trend favoring cell division in 
the UCT-MSC. 
Pathway enrichment analysis also showed that the differences between the two 
clusters in each tissue are not consistently maintained. The chord diagram (Figure 9C) 
highlights pathways overexpressed in BM-High_a and UCT-High_a, which are not the 
same.  These data confirm differences in the gene expression of non-dividing cells as a 
function of tissue of origin and suggest that the two types of MSCs are likely to have 
divergent regulatory and functional potentials. Importantly, the UCT-High_a population 
exhibit higher expression of genes involving pro inflammatory mediation, ECM 
organization and collagen biosynthesis, whereas the BM-High_a population had higher 
expression of steroid biosynthesis, the citric acid cycle and neutrophil degranulation genes 
(Figure 9C). 
Next, we examined the expression level of genes that play important roles in the 
immunomodulatory response induced by MSCs.  Focused comparison of expression of 
genes that are associated with cell adhesion, migration, immunosuppression and 
immunostimulation between the BM- and UCT-derived MSCs suggests tissue-of-origin 
and donor differences in gene activity (Figure S5). BM-High_a cells characteristically 
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overexpress transcripts encoding the membrane proteins prostaglandin synthase (PTGES2) 
and Endoglin (ENG) as well as the lysosomal protein CD63, compare to BM-High_b, 
whereas BM-High_b cells overexpress the genes CD46 (encoding a complement cofactor), 
CD47 (an integrin-associated protein), and CD146 (MCAM, cell adhesion molecule) , 
compare to BM-High_a. These genes are in general overexpressed in BM derived MSC 
compare to UCT derived MSC. BM derived MSCs have higher expression of the cell 
surface glycoprotein coding genes CD44 and CD59, as well as the nucleotidase NT5E and 
immune checkpoint molecule CD276 compare to UCT derived MSC.  Conversely, when 
comparing UCT-High_a and UCT-High_b clusters, UCT-High_a cells overexpress the 
tetraspanin regulators of motility CD151, and cell surface protein coding genes CD99, 
THY1 and CD248, while UCT-High_b overexpressed CD9. The cell surface protein 
coding gene CD81 is not significantly differentially expressed between the clusters UCT-
High_a and UCT-High_b. We looked at two genes associated with immunostimlation: 
CCL2 and CD109, which are overexpressed in UCT and BM derived MSCs, respectively. 
 We also looked at multiple pluripotent and stemness genes (Figure S6), none of 
which were found to be significantly differentially expressed between bone marrow and 
umbilical cord tissue. 
2.4. Discussion 
MSCs from various tissue sources are the subject of 4044 registered clinical trials 
(ClinicalTrials.gov- keyword: MSC as other terms with filters - not yet recruiting, 
recruiting, enrolling by invitations, and active, not recruiting; search date – August 7, 
2020).  It is thus important to develop robust high-throughput approaches for 
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characterization of diverse batches from various tissue sources in order to help evaluate 
reasons for success or failure of individual trials or patient responses.  Single cell RNA 
sequencing is a relatively unbiased approach to profile the molecular attributes of 
individual cells. Potential utility of scRNA-seq includes characterization of heterogeneity 
that cannot be observed with bulk RNA-seq, and monitoring of the effect of the stage of 
the cell-cycle on transcriptional diversity.  
Contrasting pre-freeze and post-thaw samples from 2 donors, we identified numerous 
differentially expressed genes that are associated with different types of cellular functions, 
such as cytokine signaling, cell proliferation, cell adhesion, cholesterol/steroid 
biosynthesis, and regulation of apoptosis. Previuosly, functional differences between pre-
freeze (fresh) and post-thaw MSCs were also reported by others(85). In this study, 
however, we focused on in-depth scRNA-seq analysis of post-thaw MSCs as they are 
currently being tested as cell therapy products in many clinical trials.  
Here we describe a droplet-based scRNA-seq comparison of donor, tissue-of-origin, 
and expansion conditions of out-of-thaw MSC variability, concluding that bone marrow 
and umbilical cord tissue-derived MSCs have significant differential expression that likely 
explains some of the documented differences between them, and that donor differences are 
modest yet significant. To our knowledge, six other scRNA-seq studies(5, 6, 76-79) of 
MSCs have been published, and our results are broadly concordant though with some 
important differences in emphasis.  Barrett et. al., 2019(78) used a version of SmartSeq to 
deeply profile 103 Wharton’s jelly-derived umbilical cord MSCs and 63 bone marrow-
derived MSCs, identifying 463 differentially expressed genes enriched for activity in 
numerous processes including the matrisome, coagulation, angiogenesis, and wound-
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healing via immune-regulation. The current study similarly finds a difference between cord 
tissue and bone marrow-derived MSCs. Additionally, our data also shows a cell cycle 
variability which seems to be related to the donor(78) (22).  
Each of the other studies (5, 6, 76-79) has noted that the cell cycle gene expression 
is a major source of heterogeneity within donors.  According to the Huang et. al., 2019(76)  
study, it appears the cell cycle is related to the immune regulatory potency of the MSCs. 
Previous work(77) has used a core set of G1/G2M/S markers to assign cells to each phase, 
and regressed out this source of variance before performing downstream analysis.  We 
eschewed this approach both because of concerns over the reliability of the assignments, 
and to emphasize that the proportion of cells with low expression of these genes is an 
important component of among-donor differences in both BM-MSC and UCT-MSC. 
Reported higher proliferative capacity of Wharton’s jelly-derived MSCs(78) is consistent 
with the higher proportion of mitotic genes in our UCT-MSCs relative to BM-MSCs.  
However, it should be emphasized that higher overall expression may not correlate with 
higher rates of proliferation, since expression levels may vary among donors without 
implying that a different fraction of cells are undergoing division. On the other hand, it 
appears that putative G0 cells that do not express cell cycle genes have quite different 
transcriptional properties that are directly relevant to their biological functions such as 
immunomodulatory potential.  We note that each of our samples was profiled at population 
doubling level (PDL) ranged from 12-15, eliminating passage number as a source of 
variability in our study. 
Other authors have also chosen to regress out “batch” effects before searching for 
heterogeneity, even though in each case “batch” appears to be coincident with “donor” (62, 
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77) or “Passage” (76).  In the absence of biological replication, that is, two MSC 
preparations obtained independently from the same donor, it is impossible to know whether 
differences between sample populations have a biological or technical basis.  Nevertheless, 
we estimate from principal component variance analysis that less than 10% of the overall 
expression variability is among donors/batches within each of the two clusters observed in 
both the BM- and UCT-MSC datasets (Figure 5C, Figure 7C).  We see this minor source 
of variability is donor-related in the two instances where we had technical replicates from 
the same donor (in the case of the two BM-MSC samples cultured in different laboratories). 
The cells strongly tended to be assigned to the same sub-cluster BM-High_a or UCT-
High_a. Whether or not these differences impact MSC function in clinical applications 
remains to be seen, additional large-scale comparisons with a large set of samples with 
high quality data on patient outcomes will need to be analyzed.   
In this study the transcriptomes of human bone marrow and cord tissue-derived 
MSCs were analyzed via drop-seq single cell RNA-seq. Using this approach, new 
information about MSCs emerges. First, the differences between bone marrow-derived 
MSCs and cord-tissue derived MSCs were seen. Surprisingly, pathways up-regulated in 
G0 bone marrow-derived MSCs did not correspond to the same pathways upregulated in 
G0 cord tissue -derived MSC (Figure 9C). Further, we observed differences in various 
immune regulatory genes between bone marrow and cord tissue MSCs, especially for the 
“a” cluster cells (Figure 9C). Notably, BM-High_a MSCs had higher gene expression for 
PTGES2, and the protein encoded by this gene is known to have direct or indirect role in 
immunomodulation by MSCs(86, 87). PTGES2 encodes membrane-bound prostaglandin 
synthase E2 which converts prostaglandin H2 (PGH2) to prostaglandin E2 (PGE2) that is 
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known to have anti-inflammatory/immunosuppressive effects on various immune cells, 
including macrophages, T cells and B cells(88, 89).  
MSC surface proteins are important for their significant roles in identification and 
functions(90). When we compared gene expression for surface markers that are known to 
have some immunomodulatory functions, BM derived MSCs showed higher expression 
for CD46, CD47, and CD276 whereas UCT derived MSC had higher expression for CD81. 
Surface expression of CD46 protein helps MSCs to inhibit complement binding and 
complement-mediated lysis(91). CD47 serves as a “don’t eat me” signal to avoid 
phagocytosis by engaging its cognate ligand signal-regulatory-protein alpha (SIRP alpha) 
on phagocytes(92, 93), and the interaction of CD47 with SIRP alpha is reported to inhibit 
antigen presenting cell (APC) maturation and enhance STAT3 phosphorylation and IL10 
induction in APC(94).  CD276 is known to cause immune suppression by inhibiting T cell 
function and is currently being targeted as a check point blockade therapy for cancer(95); 
however, their specific role in MSC-mediated immunomodulation is not yet confirmed. 
CD81 is one of the surface markers used to identify MSC-derived extracellular vehicles 
(EVs) but does not have any reported immunomodulatory role for MSCs; however, CD81 
coding gene is known to affect T regulatory (Treg) and myeloid-derived suppressor cell 
(MDSC) function enhancing tumor growth(96). Taken together, gene expression 
differences for surface markers related to immune response between BM and UCT-MSCs 
implicates potential differences in the immunomodulatory functions between BM and 
UCT-MSCs. Further, differences in immunomodulatory gene expression between the 
High_a and High_b clusters for both BM and UCT-MSCs indicates functional and 
phenotypic heterogeneity within each MSC product. No differences in expression of a 
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small number of pluripotent and stemness marker genes was detected between BM and 
UCT derived MSCs (Figure S6), though we note that abundance of these transcripts was 
very low which reduces power to observe differential expression.  
In summary, this study both confirms the potential for functional differences to exist 
between MSCs derived from different tissues and even donors, and that within-sample 
heterogeneity is low. The expression of cell cycle markers is a major component of 
heterogeneity among donors, and manufacturing processes may need to accommodate 
biological and technical influences on proliferative potential. These findings will help 
improve the therapeutic MSC manufacturing processes and identify the most efficient cells 
from a heterogeneous MSC population. Even though differences in the gene expression 
profile between bone marrow and cord tissue G0 MSC were found, further studies are 
needed to confirm these results as well as the impact of these differences on the clinical 
use of these cells. 
2.5. Experimental procedure 
2.5.1. Study approval 
This study was approved by the ethics committee of the institutional review boards 
at Georgia Institute of Technology and Duke University (IRB protocol no. H17348). All 
procedures involving human participants were in accordance with the ethical standards of 
the research committee. Informed consent was obtained from all participants. 
2.5.2. Human Bone Marrow MSC collection 
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Seven frozen human bone marrow-derived MSC lots from six male donors were 
purchased from RoosterBio Inc., and expanded using RoosterBio expansion protocol 
(https://www.roosterbio.com/wp-content/uploads/2019/10/A.-RoosterBio-MSC-001-
BOM-Expansion-Protocol-IF-08022016.pdf). Briefly, a BM-hMSC high performance 
media kit was brought to room temperature. Then 1 vial of Media Booster GTX 
(RoosterBio, catalog no. SU-003) was added to 500ml hMSC high performance basal 
media (RoosterBio, catalog no. SU-005). The 10million BM-hMSC vial was obtained from 
a liquid nitrogen dewar and immediately thawed at 370C for approximate 2 minutes while 
monitoring the process and removed from the water bath once a small bit of ice remained. 
Cells were aseptically transferred to a 15ml centrifuge tube and 10ml cultured media was 
added. The cells were spun down at 200g for 10 minutes and all the supernatants was 
discarded. The cell pellet was re-suspended in 10ml of culture media and transferred into 
500ml media bottle. The cells were mixed by capping and gently inverting the bottle and 
distributed (seeded at 3500-4000 cells/cm2 and 42 mL media/T225) equally into T-225 
vessels (Corning cat no. 431082). The vessels were transferred to a 370C incubator 
ensuring that the surfaces were covered with media. The vessels were observed 
microscopically from day 1 to determine percentage confluency.  Once they reached >80% 
confluency, they were harvested the next day, and cryo-preserved in Cryostor CS-10 
freezing media.  All single-cell RNA-sequencing was performed on the out of thaw cells 
directly from these frozen vials. 
Samples BM1 and BM2a were cultured in Laboratory A, while samples BM2b, 
BM3, BM4, BM5 and BM6 were cultured in Laboratory B. Samples BM2a and BM2b 
were from the same donor.   
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2.5.3. Human Cord Tissue MSC collection 
For cord tissue derived samples, six frozen human MSC samples from four male 
donors were provided by the department of pediatrics, Duke University. Cryopreserved P0 
vials were placed in a sterile bag which was itself placed in a 37°C water bath. Vials were 
thawed until the cell suspension was slushy (~2 minutes). Cell suspension from the vials 
were transferred to a 15 mL tube containing XSFM (Irvine Scientific, cat. no. 91149) using 
a sterile serological pipette and the cell suspension was mixed slowly. The cryovial was 
rinsed with 0.5 mL of XSFM and the rinse was transferred to the 15 mL tube. After mixing 
slowly, the cell count and viability was measured. The cells were mixed in the 15 mL 
conical using a sterile pipette and transfer the volume containing 3.4 x 106 cells into a 
HYPER flask containing 1.12 L of XSFM and the bottle was mixed gently. The HYPER 
Flasks were placed into a 37°C/5% CO2 incubator. The P1 cells were harvested after 5-7 
days. The P2 cells were then frozen using CS-10 freezing media and cryopreserved. The 
Cryopreserved P2 cells were shipped to us for the downstream characterizations.  All the 
single-cell RNA-sequencing was performed on the out of thaw cells directly from these 
frozen vials. 
Samples UCT1a, UCT1b and UCT1c come from the same donor. 
2.5.4. Thawing and single cell suspension preparation for Single-Cell 
RNA-Sequencing 
Frozen vials containing 1 million MSC were thawed in a 370C water bath for a 
couple of minutes. Cells were then aseptically transferred to a 15 ml centrifuge tube. Room 
temperature RPMI media (1mL) was used to rinse the cell vial and added to the cells in the 
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15 ml tube. Another 3 ml of media was added to the cells and mixed well with serological 
pipette. Cells were counted using Nucleocounter and spun down at 200 g for 10 minutes. 
The cells were re-suspended in media and counted again and processed for scRNA-
sequencing.   
2.5.5. Single-cell RNA-seq library preparation and sequencing 
The Illumina-Bio-Rad ddSEQ platform was used to process, capture, and barcode 
the cells to generate single-cell Gel Beads by following the manufacturer’s protocol. Cell 
suspensions were loaded onto a ddSEQ Cartridge along with reverse transcription master 
mix, and encapsulated and barcoded by the Single-Cell Isolator. Lysis and barcoding took 
place in each droplet. Droplets were disrupted and cDNA was pooled for second strand 
synthesis. Libraries were generated with direct cDNA tagmentation using Nextera 
technology. Tagmentation was followed by 3′ enrichment and sample indexing to prepare 
indexed, sequencing-ready libraries. The libraries were sequenced using Nextseq 
sequencing Platform on an Ilumina NextSeq in the IBB Molecular Evolution core at 
Georgia Tech (PE75, mid-output V2.5 kit). The library quality (check for primer dimers, 
adopter dimers, ethanol contamination, degradation as well as the size and concentration) 
was confirmed before each sequencing run using Agilent Bioanalyzer2100. 
All the BM-MSC samples have 2415 cells with an average 3,835 genes/cell (Table 
1) and the UCT-MSCs have 1785 cells with average 3056 genes/cell (Table 2). The BM-
MSC samples have average 28,890,505 (Table 1) reads per sample and the UCT-MSC 
samples have 33,771,805 (Table 2) reads per sample in average.  
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Confirmation that MSCs were relatively pure populations of undifferentiated cells 
was revealed by FACS analysis of cell surface markers provided by the manufacturer as a 
release criteria.  Furthermore, scRNA-seq (which is less sensitive due to high drop-out 
rates) confirmed prevalent expression of NT5E (CD73), THY1 (CD90), and ENG (CD105) 
and absent expression of CD34 among other genes (Fig. 10).   ENG was expressed on 66% 
of the cell, NT5E on 72%, and THY1 on 92%.  In contrast, each of the transcripts PTPRC, 
CD34, CD14, ITGAM, CD79A, CD19, and HLA-DRA were detected in less than 0.5% of 
the cells. 
The colors represent the average expression of the genes per cell. The scale is from low 
expression of 0 (gray) to high expression of 1.5 log counts per million (blue). The size of 
the dots represents the proportion of cells in each cluster that express the gene. 
 
2.5.6. Data Analysis 
Sample demultiplexing and gene counts were extracted using the Illumina SureCell 
pipeline. The raw reads were trimmed, and the gene-barcode matrix was generated. 
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Figure 10. Dot plot displaying the average expression for cell adhesion and 
migration and immunomodulatory function-associated genes 
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SureCell was also used to filter and align the samples and to generate gene-cell UMI count 
matrices. The seven samples from bone marrow were sequenced in three different batches, 
and the six samples from cord tissue were sequenced in two batches. 
Downstream analysis was initiated with SC3 software(83) for cell clustering. 
Owing to the high proportion of zero counts in most cells (as is typical of dropseq data), 
we elected to perform differential expression analysis on pools of pseudo-cells whose 
profiles have a distribution of read counts that closely resembles that of bulk RNAseq.  
Custom R scripts were used to generate pools of pseudo-cells by pooling groups of 20 cells 
within each sample and cluster, and then summing their gene count. The gene expression 
values from the pseudo cells were normalized to counts per million before using EdgeR(97)  
for normalization and differential expression estimation. Default likelihood ratio tests 
assuming negative binomial distributions were performed in EdgeR to evaluate the 
significance of differential expression. Ten permutations of this procedure were performed, 
and the average differential expression and negative-log P-values were computed, and 
genes significant with an FDR less than 5% were selected for downstream gene ontology 
analysis. Then gene ontology was performed on the differentially expressed genes using 
GSEA(98) and ToppGene(99) tools. 
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CHAPTER 3. CHARACTERIZATION OF THE EFFECT 
OF CYTOKINES ON ENHANCEMENT OF 
MESENCHYMAL STROMAL CELL FUNCTION 
3.1. Abstract 
Enhanced mesenchymal stromal cells are subject of multiple studies for their 
immunosuppressive capacities. Cytokines like TNF⍺ or IFN𝛾 are known to modify the 
anti-inflammatory effects of MSC. While previous studies used both TNF⍺ and IFN𝛾 as 
MSC immunomodulatory enhancers, it is not clear how these cytokines activate the 
immunosuppressive function of MSC. Previous in vitro studies have also shown 
suppression of lymphoid cells (B cells, NK and T cells), when they are exposed to enhanced 
MSC. The mechanism by which these cells suppress the immune system is yet to be 
clarified. Here I characterize the expression profiles of MSC treated with TNF⍺ or IFN𝛾, 
using bulk RNA seq. 48 hours after exposure to the cytokines, MSC treated with IFN𝛾 
have higher levels of expression of immunosuppressive markers, even though compared to 
the control MSC, both treatments seem to activate similar MSC pathways. I also 
characterize the gene expression profile of T cells after exposure to IFN𝛾-treated MSC 
(𝛾MSC) using single cell RNA seq. Suppression of the T cell mitotic cell cycle, as seen in 
previous studies, is confirmed, but differences in the response of two types of T cells (CD4 





When the body detects a foreign antigen, the immune system responds by activating 
a variety of immune cells(100). One of the first responder to the foreign antigen are the T 
cells. When activated, these T cells secrete cytokines that activate but also regulate the 
immune response(100, 101). 
T cells are produced in the bone marrow and they are capable of recognizing a large 
variety of antigens. Some T cells recognize self-antigens, in which case they are generally 
inactivated on the thymus, the organ where T cell maturation takes place.  This inactivation 
process is called tolerance induction. Tolerance usually ensures that T cells do not attack 
the cells that present self-proteins of the body. When tolerance induction fails, T cells that 
do recognize self-antigens are released and attack cells from the body. The malfunction of 
this process leads to different autoimmune diseases. 
Similar self-damaging attacks of the immune system can also be seeing in Graft vs 
Host Disease (GvHD). In this case, the patients receive an organ transplant which contains 
donor’s T cells. These T cells recognize the host cells as foreign and activate the immune 
system and attack the host cells. GvHD is the primary cause of morbidity and mortality 
after hematopoietic cell transplantation (HCT), afflicting as many as one half of all 
recipients(102). 
Current treatments for many immune related diseases include the use of anti-
inflammatory drugs and potent immunosuppressive and immunomodulatory agents(103). 
Despite their effect on immune responses, these agents are not uniformly effective and are 
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associated with substantial toxicities.  They may also increase the risk of opportunistic 
infections or recurrent leukemia(104).  
In recent years, researchers have contemplated the use of stem cells to treat 
autoimmune disorders. Even though cell therapy is already been used in non-responding 
patients (patients that do not respond to the standard treatments), the study of these cells is 
of increasing importance. Mesenchymal stem cells are known to have an inhibitory effect 
on immune cells including naïve, memory and activated T cells, B cell, NK cells and 
dendritic cells(105, 106). The immunosuppressive effect of the MSC have been shown to 
be enhanced by adding different kind of cytokines in the culture media(107-111).  
There are two cytokines used in research to enhance the immunosuppressive activity 
of the MSC: IFN𝛾 and TNF⍺(109,	111,	112). These two cytokines are pro-inflammatory 
cytokines, secreted by activated T cells. Even though it is known that enhanced MSC 
suppress the activity of some immune cells and can also induce apoptosis, the interaction 
between MSC and the immune cells has not yet been defined in terms of gene 
expression(105, 113-115). This suppression can be done by different pathways such as the 
interferon mediated suppression(116) and TNF signaling(117). 
One of the main problems when trying to analyze the effect of MSC on the immune 
system is the reproductivity of the findings. As described in Chapter 2, MSCs can come 
from different tissues and donors, which impacts their therapeutic potential.  In addition to 
tissue and donor related variability, these cells may be treated with different cytokines for 
a period of time between 48 to 72 hours, to enhance their immunomodulatory capacities, 
creating a cytokine and time related variability.  
 49 
This Chapter aims to assess the effect of different enhancement treatments on bone 
marrow derived MSC gene expression profiles, and subsequently the effect of the enhanced 
MSC on the gene expression profiles of mouse T cells. To accomplish this, I characterize 
the gene expression profiles of bone marrow derived MSCs treated with IFN𝛾 and TNF⍺. 
I then describe the gene expression profiles of these cells at different times after the 
exposure to cytokines (T0, T48 and T72). Finally, I characterize the gene expression profile 
of mouse T cells after exposure to enhanced bone marrow derived MSC. 
3.3. Results 
3.3.1. Comparison of the gene expression profile of Mesenchymal Stem 
Cells from different donors following exposure to IFN𝛾	and	TNF⍺ 
A total of 12 samples from 4 different donors were collected: each donor has 3 
samples, one cultured in normal media with no cytokines added, one in media + IFN𝛾 and 
one in media + TNF⍺. These samples were then sequenced using bulk RNA-seq.  The first 
5 principal components (PC) capture 88% of the variance in gene expression, and as show 
in Figure 12A,B treatment is the major variance component (62.4% weighted contribution, 
mostly due to PC1 and PC2), but donor is also an important variant component as well 
(36.1%, mostly PC3-5). The PCA plot in figure 11C, shows that IFN𝛾 treated samples have 
the most extreme response, as they separate from the control and TNF⍺ treated samples	
along PC1, whereas TNF⍺ treatment induces a greater change along PC2.  Donor effects 
are also observed, donor, with Donors 1 and 2 having more negative scores, and donors 3 
and 4 more positive (toward the top of the plot) regardless of the control or treatment status. 
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(A) Treatment is the major source of variability within the MSC samples, followed by 
donor. (B) the first 5 principal components capture 88% of the total variability. Principal 
components 1 and 2 represent mostly the treatment variability, while principal components 
3, 4 and 5 represent the donor variability. (C) PC1 clearly separates the IFN𝛾 treated 
samples (green) from the TNF⍺ (blue) and control (salmon) samples. 
 
Differential expression analysis contrasting the IFN𝛾 treated and control samples 
revealed that 3,561 genes were significantly differentially expressed at the 5% False 
Discovery Rate: 1,885 genes were overexpressed in IFN𝛾 treated samples and 1,676 genes 






























































































Figure 11. Principal variance component analysis and principal and Principal 
component analysis. 
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significantly differentially expressed between TNF⍺ treated samples and control samples: 
739 genes were overexpressed in TNF⍺ treated samples and 484 genes were overexpressed 
in control samples. 
Chord diagram summarizing differential expression and enriched pathways in the IFN𝛾 
(pink) and TNF⍺	(purple) treated samples, compared to the control samples. 
Gene ontology analysis revealed that similar pathways were overexpressed in both 
types of treated samples compared to the controls. Among the pathways overexpressed in 
the treated samples, interferon signaling, antigen processing and presentation and cytokine 
signaling in the immune system stand out (Figure 12). Each ark links a gene indicated on 
Figure 12. Differentially expressed genes and pathways in IFN𝛾 and 
TNF⍺ treated samples, compared to the control samples 
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the left to a pathway on the right, and in almost half the cases statistically significant over-
expression is seen the Interferon, TNF signaling, and adaptive immune pathways after both 
treatments.  The treated samples thus overexpress genes and pathways related to the 
suppression of the immune system. 
 I also performed differential expression analysis between IFN𝛾 and TNF⍺ treated 
samples. 4,796 genes were found to be significantly differentially expressed, with 2,397 
gene overexpressed in IFN𝛾 treated samples and 2,399 genes overexpressed in TNF⍺ 
treated samples. The gene ontology analysis performed in these genes (Figure 13) shows 
an enrichment in pathways related to gene expression, translation and metabolism on the 
Figure 13. Chord diagram displaying some of the enriched pathways in IFN𝛾 
treated samples and TNF⍺ treated samples, when compare to each other. 
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samples treated with TNF⍺, while the samples treated with IFN𝛾 overexpressed pathways 
related to the repression of the immune system. 
Table 3. Immunomodulatory markers. 
 The differential expression of immunomodulation markers is summarized in Table 
3 and Figure 14. Each of these markers is up-regulated following either cytokine treatment, 
but consistently the level of overexpression of the immunomodulation markers is higher 
when the samples are treated with IFN𝛾 than with TNF⍺.		Consequently,	the	remainder	
of	the	study	focused	on	MSC	treated	with	IFN𝛾.   
(A)Volcano plot of the differentially expressed genes between IFN𝛾	 treated MSC and 
control samples. (B)Volcano plot of the differentially expressed genes between TNF⍺	
treated MSC and control cells. In both plots, the dots in red represent the 
immunomodulatory markers, showing a higher level of overexpression in the samples 
treated with IFN𝛾. 
PTGES2 ENG CD63 CD44 CD46 CD47 
NT5E CD276 CD151 CD99 THY1 CD248 
IDO2 NOS1 NOS2 CCL2 CD151 MCAM 















































































Figure 14. Volcano plots of the differentially expressed genes between IFN𝛾 and 
TNF⍺ treated samples and control samples. 
 54 
3.3.2. Evaluate the gene expression profile of (𝛾MSC) through time: at T0, 
T48 and T72 
	
	
(A) PC1 plots separated the samples by treated and control, while PC2 separates the 
samples by donor. (B) The major source of variability in the gene expression profile of 
these cells is the time (0h, 48h and 72h), followed by the donor variability. (C) Time 
variation is represented by PC1 and PC4, while donor variation is represented by PC2 
and PC3. PC4 represents a combination between donor and time variance. 
In	order	to	evaluate	the	time	course	of	expression	profiles	of	(𝛾MSC)	through	
time	(at	T0,	T48	and	T72	hours),	9	bone marrow derived MSC samples from 3 different 
donors were sequenced using Bulk-RNA: each donor has a control sample and two treated 






















































































Figure 15. Principal variance component analysis and principal component 
analysis. 
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exposure to IFN𝛾 (Figure 15).	The first 5 principal component account for 94% of the total 
variance. Principal component 1 and 4 represent the time related variance (57.6%), while 
principal components 2 and 3 represent the donor related variance (32.4%). 
2,372 genes were differentially expressed between the control samples at T0 and 
the treated samples sequenced 48 hours after exposure to IFN𝛾, at a FDR lower than 0.05: 
1,077 genes downregulated and 1,295 upregulated at T48, including JAK2, STAT1, 
STAT2, STAT3, MYD88, IRAK4, IRF3, IRF9, IRF7 and many HLA genes, consistent 
with expectations of a strong interferon response.  
Very similar results were obtained contrasting the 72hr treatment with baseline, but 
only 34 genes were observed to be significantly differentially expressed between the T48 
and T72 samples.  There was a slight trend toward enhanced differential expression at 72 
hrs, but no obvious induction or repression of new pathways.  This result shows that the 
interferon response is consistent for up to three days of treatment.  
Gene set enrichment analysis detected differential expression of genes involved in 
TGFβ signaling, reactive oxygen species generation, KRAS signaling, cholesterol 
homeostasis and bile acid metabolism, as well as the inflammatory and Interferon gamma 
responses. 
3.3.3. Effect	of	𝛾MSC	on	T	cells	
I next asked what impact cytokine treatment has on the ability of MSC to modify 
the gene activity of T cells in vitro.  Murine T-cells were cultured with or without 𝛾MSC 
conditioned media, resulting in 6 scRNA-seq samples for comparison: 3 representing 
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activated T cells in different cell cycle phases (TG0, TG1, TSG2) and 3 representing 
suppressed T cells, also in different cell cycle phases (G0𝛾MSC, TG1𝛾MSC, TSG2𝛾MSC).  
Each cell cycle phase was captured by flow sorting based on … 
 
Figure 16. Principal variance component analysis and principal component analysis. 
(A) Treatment variation is represented by PC1 and PC4, while donor variation is 
represented by PC2 and PC3. PC4 represents a combination between donor and time 
variance PC1 plots separated the samples by treated and control, while PC2 separates the 
samples by donor. (B) The major source of variability in the gene expression profile of 
these cells is the time (0h, 48h and 72h), followed by the donor variability. (C). 
PCA was again performed on the single cell data, as summarized in Fig. 16A and 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































due to the first 5 PC, while the cell cycle corresponds to just 5.4% (Fig.16B). PC1 separates 
the samples mostly by treatment, on the right of PC1 are the samples treated with yMSC, 
and on the left, the control samples. On the other hand, PC2 separates the samples by cell 
cycle phase and treatment (Fig.16A). High PC2 corresponds to cells in S, G2 and M phases, 
low PC2 correspond to the cells in G0 phase. Cells in G1 phase are located in between.  
Differential expression and gene ontology analysis performed on the significantly 
differentially expressed genes (FDR < 5%) resulted in the following findings:  
TG0 vs G0yMSC 
Figure 17. Chord diagram of the enriched pathways from the treated vs control 
samples. 
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7678 genes were differentially expressed between the G0 T cells treated with 
untreated and interferon-gamma exposed MSC. The activated T cells in G0 phase express 
genes involved in T cell activation, T cell receptor signalling pathway, T cell signal 
transduction and Th cell differentiation, among others. On the other hand, the T cells in G0 
suppressed with yMSC treatment expressed genes involved in cellular responses to stress, 
degradation of cyclins, apoptosis and mRNA destabilization (Figure 17). 
TG1 vs G1yMSC 
7769 genes were found to be differentially expressed. The activated T cells in G1 
phase express genes involved in translation, cell cycle, DNA repair and mitotic G1-G1/S 
phase. The T cells in G1 suppressed with yMSC and the T cells in G0 suppressed with 
yMSC have a similar gene expression profile.  The T cells in G1 suppressed with yMSC 
overexpress genes involved in cellular response to stress, degradation of different cyclins 
but also innate immune system genes (Figure 17).  
TSG2M vs SG2MyMSC  
7390 genes were found to be differentially expressed in the mitotically active T cells. 
The activated T cells in S, G2 and M phases express genes involved in the cell cycle, DNA 
repair and translation, while the T cells in S, G2 and M phases, suppressed with yMSC, 
express genes involved in cellular response to stress, rRNA modification, innate immune 
system signaling and MHC mediated antigen signaling processing and presentation (Fig. 
17). 
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In a final analysis, cell markers (CD4, CD8A, CD8B) were used to differentiate 
CD4+ and CD8+ T cells (Table S1). CD4+ cells predominate with about a 2:1 ratio to 
CD8A+ in all cycle phases without treatment. However, after the T cells are treated with 
yMSC the global ratio of CD8 to CD4 positive cells is altered toward parity, implying a 
significant reduction in the proportion of CD4+ relative to CD8+ T cells. Notably as well, 
yMSC treatment reduces dramatically the proportion of cells in S/G2 (Figure 18), 
consistent with suppression of T-cell division. 
3.4. Discussion 
MSC are currently used for cell therapy in different kinds of diseases. Due to their 
immunomodulatory capacities, these cells are being tested in different diseases related to 
the immune system(115, 118-121). Even though these cells are currently used in cell 
therapy, it is important to characterize them and the effect they have on the immune system. 
The immunomodulatory capacities of MSC in vitro can be enhanced by exposure to 
immunosuppressive cytokines(109, 111, 112). INFγ and TNF⍺ are both use to enhance the 
Figure 18. Abundance of CD4 and CD8A T 
cells per sample. 
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immunomodulatory capacities of the MSC, making them an interest asset for immune 
diseases.   
Comparing bone marrow derived MSC samples, before and after exposure to INFγ 
and TNF⍺.,	both	treatments	resulted	in overexpression of immunomodulatory markers, 
like PTGES2, ENG, NT5E, IDO1 and IDO2, and enrichment of pathways related to the 
immune system, like cytokine signaling and antigen processing and presentation, compare 
to the control samples. Even though these treated samples overexpressing similar genes 
and pathways compare to the control samples, the PCA analysis show they have different 
gene expression profiles, with the TNF⍺	 treated samples being placed near the control 
samples. Since the PCA analysis suggested there is a difference between the INFγ and 
TNF⍺	 treated samples, I examined more closely the expression of various immune 
suppressive markers in the different samples. Once again, the level of overexpression of 
these markers when using INFγ was greater than the levels of overexpression of the same 
markers when using TNF⍺, relative to control samples. Two possible explanations are that 
there could be a delay in the time course of full activation of the TNF⍺ treated MSC, or 
that the activation of these genes in the TNF⍺ treated samples never reaches the levels 
observed in INFγ treated samples.  Since the difference in treatment effects was observed 
in four different donor MSC samples, it is unlikely that it reflects inter-individual 
differences in the expression of a key receptor, but rather is intrinsic to the wiring of MSC 
to receive different cytokine signals. 
  Another potential source of variability when using MSC to suppress the immune 
system, is the culture time. Previous studies have determined the activation time of these 
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cells to be 48 hours after being expose to the cytokines, recommending these cells to be 
used at this time(109, 122). Unfortunately, this is not always the case. MSC are cultured in 
conditioned media for a period of 48 to 72 hours before these are used for research or 
therapy. This procedure variability raises the question of whether the activation period of 
these cells affects their function: are the MSC still active after 72 hours, or do they have to 
be used exactly 48 hours after the exposure to the cytokines. Our results suggest that there 
is little effect of the additional 24 hours incubation, since the gene expression profiles of 
the samples sequenced after 48 hours compare to the samples sequenced after 72 hours of 
exposure to INFγ were very similar. Only 34 genes were found to be significantly 
differentially expressed at an FDR lower than 0.05, suggesting the function of these cells 
remain the same from 48 to 72 hours. 
The third experiment in this study focused on the effect of INFγ enhancement of 
MSC, with respect to modulation of co-cultured T cells.  Previous studies(123-126) have 
shown there is suppression of the T cell mitotic cycle upon exposure to cytokines, which 
led us to prepare samples at separate cell cycle stages (G0, G1 and S/G2/M) using flow 
cytometry. These cells were then separated into two groups, INFγ treated and control cells. 
For this analysis, single cell RNA seq was used to characterize the gene expression profile 
of each cell individually, rather than bulk RNAseq, in order to consider whether there is 
heterogeneity in the cell-to-cell responses. The single cell expression analysis confirmed 
the suppression of the cell cycle by the enhanced MSC and also showing an increase on 
the number of cells in the G0 phase on the treated samples. Contrary to previous 
studies(111), INFγ treated MSC don’t seem to suppress the T cell activation. Furthermore, 
expression of the cell markers CD4 and CD8A showed an important decrease in the 
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abundance of CD4+ T cells in the treated samples compare to control sample, suggesting 
the γMSC promote differentiation of T-cells away from the CD4 helper profile toward the 
more cytotoxic CD8 state.  
In summary, this study showed there is a difference on the gene expression profile 
of the MSC when they are activated with INFγ or TNF⍺, suggesting a difference in the 
activation of the immunomodulation capacities related to the cytokine. When INFγ is used 
to activate the MSC immunosuppression capacity, there is no significant difference on the 
expression profile of these cells between 48 and 72 hours after exposure to the cytokine. 
Finally, I demonstrated that γMSC have the capacity to suppress cell cycle progression of 
T cells, and also to influence the balance of helper and cytotoxic T cell types. These in vitro 
observed properties need to be reassessed in vivo by examining the expression profiles of 
resident T-cells after MSC therapy.  
3.5. Methods 
3.5.1. Data Analysis Bulk RNA 
Quality control of the short sequencing reads was performed using FastQC version 
0.11.5 (127)  and the alignment of the fastq files to either mouse (mm10) or human 
reference genomes (hg38) was performed using the STAR aligner version 2.5.2a (128), 
using quantMode function to extract the gene count matrix. 
The bulk RNA seq analysis was done using EdgeR version 3.26.8 (97). The gene 
expression values from the samples were normalized to counts per million and differential 
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expression was assessed using the default likelihood ratio tests assuming negative binomial 
distributions. 
3.5.2. Data Analysis of single cell RNA 
Sample demultiplexing and gene counts were extracted using the Illumina Sure cell 
pipeline. The raw reads were trimmed, and the gene-barcode matrix was generated. 
SureCell was also used to filter and align the samples and to generate gene-cell UMI count 
matrices.  
Downstream analysis was initiated with Seurat software version 3.2.0(82) for 
normalization and PCA. Owing to the high proportion of zero counts in most cells (as is 
typical of dropseq data), we elected to perform differential expression analysis on pools of 
pseudo-cells whose profiles have a distribution of read counts that closely resembles that 
of bulk RNAseq.  Custom R scripts were used to generate pools of pseudo-cells by pooling 
groups of 20 cells within each sample and cluster, and then summing their gene count. The 
gene expression values from the pseudo cells were normalized to counts per million before 
using EdgeR version 3.26.8 (41) for normalization and differential expression estimation. 
Default likelihood ratio tests assuming negative binomial distributions were performed in 
EdgeR to evaluate the significance of differential expression. Ten permutations of this 
procedure were performed, and the average differential expression and negative-log P-
values were computed, and genes significant with an FDR less than 5% were selected for 
downstream gene ontology analysis. Then gene ontology was performed on the 
differentially expressed genes using GSEA(98) and ToppGene(99) tools. 
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CHAPTER 4. COMPARISON OF BONE MARROW 
ASPIRATE CONCENTRATE FROM HEALTHY AND 
OSTEOARTHRITIC DONORS USING SINGLE CELL RNA-
SEQ  
4.1. Abstract 
Osteoarthritis is degenerative joint condition affecting more than 30 million adults in 
the US. Even though this is a common disease, the is not cure for it. The current treatment 
is based on lowering the levels of pain and inflammation with the use of steroids and 
ibuprofen. Physical therapy or surgery are used in patients nonresponding to the anti-
inflammatory drugs. Recent studies have showing promising results in the use of cell 
therapy as a treatment for osteoarthritis. Bone marrow aspirate concentrates (BMAC) are 
used as treatment for osteoarthritis. They contain a low percent of mesenchymal stem cells, 
which are multipotent cells with immunosuppressive capacities. The BMAC used normally 
autologous, which means they come from the patient itself. In this study, I compare the 
gene expression profile of the different immune cells contain on the BMAC samples from 
osteoarthritic (OA) patients and non-osteoarthritic (non-OA) donors, showing differences 
in the abundance of the cell types, like NK, T cells, mature B and monocytes, among others, 
which seems to be due to the individual. Beside the abundance variation, I showed a 
difference in the gene expression profile of the cell depending on the donor condition, OA 
and non-OA. The OA samples show an enrichment in genes involved in inflammatory 




Osteoarthritis is a common degenerative joint condition, usually occurring in the 
knee, hip, hands or spine, which currently affects over 32.5 million adults in the US, 
according to the CDC website (https://www.cdc.gov/arthritis/basics/osteoarthritis.htm). To 
date, there are no licensed disease-modifying osteoarthritis drugs (DMOADs), capable of 
inhibiting the structural changes associated with the disease.  Treatment plans involve 
medication and exercise regimes to reduce pain and improve joint function, but eventually 
provide no options for total recovery.  There is thus considerable interest and investment 
in use of cell therapy to circumscribe these rather drastic interventions.  
The osteoarthritic joint typically develops after ischemic or mechanical damage to 
the subchondral bone and articular cartilage and is characterized by a progressive 
breakdown of cartilage, the development of subchondral bone sclerosis and osteophytes, 
and hypertrophy and inflammation of the synovial membrane. Since the inflammation is 
considered low grade, this condition has been described as “non-inflammatory” arthritis. 
The degradation of cartilage, and the subsequent phagocytosis of the fragments by the 
synovium, render the synovium hypertrophic and activated. Inflammatory cytokines and 
proteolytic enzymes further degrade the cartilage matrix, and this is exacerbated by the 
involvement of T cells, B cells, monocytes and macrophages(129-132).  
Bone marrow aspirate concentrate (BMAC) is used in clinical trials to improve 
symptomatic osteoarthritis pain and joint function(133-135). The BMAC can come from 
the patient itself, autologous, or from a donor, allogeneic. Since bone marrow aspirate only 
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contains 0.001-0.01% mesenchymal stromal cells (MSC) of the nucleated cell 
fraction(136), it requires centrifugation to concentrate cells, growth factors and platelets. 
The resulting BMAC is a more concentrated source of lymphocytes (13%), eosinophils 
(2.2%), monocytes (1.3%), basophils (0.1%) platelets, and MSC (0.03%) (137, 138).  
The factors responsible for BMAC’s activity are unknown, but thought to be related 
to platelets, their associated growth factors and the MSC fraction. It has been proposed that 
the elderly population have a lower MSC count, with reduced proliferative and 
chondrogenic capacity(139). BMAC isolates with higher cell concentration have been 
suggested to result in better treatment outcomes(140) and it has also been proposed that 
patients with mild OA, Kellgren-Lawrence grade 2 (KL2) experience better outcomes with 
BMAC treatment than those with advanced OA (KL4)(47, 141). BMAC administration has 
been reported to minimize fibrocartilage formation. Monocytes, and their progeny, 
osteoclasts and macrophages, are thought to drive the pathogenesis of OA and so reducing 
their activation could be important in preventing the progression of the condition. Anti-
inflammatory mediators such as VEGF, IL-1RA, and PDGF, derived from platelets, could 
invoke a response to bring regeneration in the joint. BMAC is often used as an adjunct 
therapy, and given its variability patient to patient, this complicates any proof of efficacy.  
While BMAC samples from the patient itself are one of the options for cell therapy to treat 
OA in non-responding patients, it is crucial to understand the different in function between 
OA and non-OA derived BMAC.  
Single cell RNAseq has become a very valuable tool to investigate the cell 
populations present and the gene expression levels of tissue samples. In order to understand 
the composition of BMAC and its attributes which may contribute to a potential mode of 
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action, particularly for easing of joint pain, single cell RNAseq has been used to analyze 
BMAC samples in this study.   
This study aimed to understand the BMAC composition and gene expression profile 
variability due to the donors and the donor’s condition (OA or non-OA). A single cell 
RNAseq library of BMAC from 21 healthy control individuals(142) was used to compare 
with single cell RNAseq analysis of BMAC isolated from osteoarthritic patients enrolled 
in an osteoarthritis trial (the MILES study). OA grade, age and BMI are co-factors 
considered in the comparison, along with activation state of monocytes and pro-
inflammatory/anti-inflammatory mediators.    
4.3. Results 
Evaluation of the content of bone marrow aspirate concentrates from 
osteoarthritis patients compared to bone marrow aspirate concentrates from 
healthy donors. 
A. B.
Figure 19. UMAP displaying the clusters and cell types present in the BMAC samples 
from OA and non-OA. 
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For this analysis I had 21 samples from 21 OA patients, and 25 samples from 19 non-OA 
donors(142), sequenced using single cell RNA sequencing. The average read depths of 
both datasets were similar with x0,000 reads and y,000 uniquely expressed transcripts per 
cell.  The samples clustered in 25 groups. These subgroups were then assigned likely cell-
type identities using published cell markers(142). All the cell types were present in both 
OA and non-OA datasets (Fig. 19). None of the subgroups correspond to MSC cells, though 
this is not surprising due to the expected low abundance of MSCs in BMAC.  
Since this study focuses on the immune related cells and the anti/pro-inflammatory 
mediators, the erythroid cells were excluded from the remaining analysis. The data was re-
clustered with Seurat, and the cell types were again identified using published gene markers 
(142)(10.1172/jci.insight.124928). In this case, we were able to identify all the previous 
cell types (without the erythroid cells) and a MSC cluster (Fig. 20A). Additional cell 
markers were also used to identify the MSC cluster (Fig. 20B). 
A. B.
Figure 20. UMAP of the cell identification after removal of erythrocytes. 
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Figure 21A shows the content of the BMAC is not the same between OA and non-
OA donors, as there is high variability of the cell ratios between the two conditions. A 
principal component variance analysis was performed to elucidate the major sources of 
variation between samples within conditions. As expected, cell type was the major source 
of variation (57.6% of the total variance), followed by the donor at just (3.7% of the total 
variance), BMI, sex, age and KL score (Figure 21B), suggesting the variance between 
samples is mainly due to the donor and the condition. An anova test was done to analyse 
the variation of the cell abundance depending on the sex, BMI, age and KL score. Some 
cell types such as monocytes, NK, progenitor B and MEGA shown a significant variation 
on the cell abundance related to the KL score and sex (Figures S10 and S11).  
(A) Cell type distribution between conditions. (B) Principal component variance analysis. 
4.3.1. OA versus non-OA gene expression profiles 
Differential expression analysis was done between the OA and non-OA sample for 


























Figure 21. Sources of sample variability.  
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parameters from Seurat, using FDR 5% as the significance threshold. I was not able to 
perform a DE analysis on the MSC due to their low count. 
Table 4. Differential expression analysis between OA and non-OA BMAC. 
Cell type T 
cells 













Number of DE 
genes 








231 284 533 291 437 267 281 311 284 
Pathway analysis shows overexpression of genes and pathways related to immune 
system activation, in the OA samples compare to the non-OA samples (Figure 22). 
Figure 22. Chord diagram displaying the genes overexpressed in some of the 
cell types from OA derived BMAC compare to non-OA BMAC. 
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4.4. Discussion 
Osteoarthritis is a common degenerative joint condition with no cure. The current 
treatment aims to reduce the joint pain and improve its function. Cell therapy is becoming 
a popular treatment for patients with OA(143). BMAC is often used as an adjunct therapy, 
but given its variability patient to patient, it is complicated to proof its efficacy.  It is then 
critical to have a clear understanding of the function of cells used for this purpose and their 
variability. BMAC contain multiple cells types like T cells, monocytes, B cells and MSC. 
It’s not clear whether the patients’ outcome is due to a mixture of contributions from all 
the cell types included in the BMAC or if it’s only due to the effect of the MSC 
immunosuppression capacity enhanced by the pro inflammatory cytokines present in the 
OA patient. 
My preliminary analysis shows that the main source of variability in the BMAC gene 
expression profiles, beside the cell types variability, is due to the cell type, follow by the 
donor (sample) variability (Figure 21B). Sex, BMI and age seem to have a lower effect on 
the cell variability. The differential expression analysis further shows significant 
differences on the gene expression profiles of the cell types present in the BMAC related 
to the presence or absence of osteoarthritis. The gene ontology analysis performed in the 
significant differentially expressed genes suggest the cell types from the OA patients tend 
to have a higher activity of immune related functions such as TCR signaling, BCR 
signaling and T cell activation.  
Previous studies have shown the role of the different immune cell types on the 
progression of the OA by secreting catabolic cytokines and stimulating protease destruction 
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of cartilage matrix(144, 145). The secretion of pro inflammatory cytokines by immune 
cells is an indicator of the disease status and progress. Since BMAC from OA patients have 
a higher expression of immune related pathways and pro inflammatory cytokine, it may be 
helpful to consider the use of BMAC form healthy donors as treatment for osteoarthritis.  
This would necessarily entail allogeneic specimens, which may however raise concerns 
over donor-mediated immune reactions. 
4.5. Experimental procedure 
 Single	cell	RNA-seq	and	data	pre-processing	
Cryopreserved samples were thawed in 37oC water bath for ~2 minutes. A washing 
step was performed immediately after diluting the samples in 10ml PBS+0.1% BSA. The 
cells were counted for each sample using AOPI dye on Cellometer (Nexcelom) and 
Nucleocounter (Cemometec) automated cell counters. The samples were then processed 
through a magnetic removal of dead cells using the Dead Cell clean-up kit (Miltenyi 
Biotek, cat. no. 130-090-101) according to the manufacturer’s protocol. 
scRNA-Seq was performed using 10X Genomics Single Cell 3′ Solution, version 3.1, 
according to the manufacturer’s instructions (protocol rev C). Libraries were sequenced on 
Nextseq500 (Illumina) and Novaseq6000 (Illumina). The resulting data were analyzed 
using Cell Ranger version 3.1.0 (10X Genomics). The OA samples were sequenced in 6 
batches.  
4.5.1. Data Analysis 
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Quality control metrics were used to select cells with a mitochondrial gene percentage less 
than 50% and at least 200 genes detected. The data were then analysed using Seurat’s 
Louvain clustering algorithm, with a resolution of 0.4. The visualization was done using 
UMAP(146). We used Seurat Integration pipeline(82) to integrate the OA and non-OA 
datasets. This method aims to identify shared cell states that are present across different 
datasets, even if they were collected from different individuals, experimental conditions, 
technologies, or even species. It focuses on the identification of ‘anchors’ between pairs of 
datasets. These represent pairwise correspondences between cells from each dataset. A list 
of markers(142) was used to identify the different cell types present in the BMAC. A 
differential expression analysis between OA and no OA, for each cell type, was done using 
the Wilcoxon rank sum test from Seurat. We used ToppGene for the gene ontology 
analysis. The principal component variation analysis included cell type, donor, BMI, sex, 




CHAPTER 5. CONCLUSION 
The immune system is a complex system that protects the body against diseases. It 
detects a variety of pathogens, as well as cancer cells, by differentiating them from the 
organism's own healthy tissue. Malfunction of the immune system can cause autoimmune 
diseases, inflammatory diseases or cancer. There are more than 80 different autoimmune 
diseases(147), over 100 different cancers(148) and many more diseases that involve the 
immune system affecting people around the world. 
 Treatment for immune related diseases varies going from Acetaminophen(149) to 
decrease the pain, to chemotherapy(150), to kill fast growing cells. For many of these 
diseases, such as autoimmune diseases and graft versus host disease, the gold standard 
treatment are not always effective, leading to an important unmet medical need.   
 Cell therapy has become a target for research as possible treatment for these 
diseases. Multiple cells are used for cell therapy such as mesenchymal stem cells, 
hematopoietic stem cells and bone marrow aspirate concentrates. These cells can also come 
from different tissues and they can be extracted from the patients itself or from a donor. 
Even though the studies about cell therapy show promising results(151-157),these sources 
of variabilities across the field confound the ability to compare clinical trial results and 
contributed to a lack of conclusive data to support their potential for clinical use(4). It is 
then crucial to provide a characterization of diverse batches from various tissue sources in 
order to help evaluate reasons for success or failure of individual trials or patient responses. 
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 The second chapter of this thesis focuses on the study of the MSC transcriptomic 
profile variability related to the tissue of origin and the donor, using scRAN-seq 
technology. This analysis shows the cells derived from the same tissue cluster in two group, 
a group of cells in G0 phase and a group of cells with high expression of mitotic genes. 
This difference seems to be related to the donor. Previous studies(5, 6, 76-79) have also 
show the cell cycle gene expression as a major source of heterogeneity.  According to the 
Huang et. al., 2019(76)  study, the cell cycle is related to the immune regulatory potency 
of the MSCs, reason why I did not regress out this sources of variance before performing 
downstream analysis as done in previous work(77). I also demonstrate that bone marrow 
and umbilical cord tissue derived MSC have different transcriptomic profiles. The 
umbilical cord tissues derived MSCs show a higher expression of mitotic genes compare 
to bone marrow derived MSC. The G0 cells have different transcriptional properties that 
are directly relevant to their biological functions such as immunomodulatory potential. 
These differences likely explain some of the documented differences between them. The 
donor differences having an impact on the gene expression profile of these cells can also 
contribute to the difference seen in clinical trials. 
On the third chapter of this thesis, I focused on the immunomodulatory capacities of 
the bone marrow derived MSC and their effect on the T cells gene expression profile. The 
immunomodulatory capacities of MSC in vitro can be enhanced by exposure to 
immunosuppressive cytokines such as INFγ and TNF⍺(109, 111, 112) creating a source of 
variability. The comparison of bone marrow derived MSC samples, before and after 
exposure to INFγ and TNF⍺, using bulk RNA-seq, shows an overexpression of 
immunomodulatory markers, like PTGES2, ENG, NT5E, IDO1 and IDO2, and enrichment 
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of pathways related to the immune system, like cytokine signaling and antigen processing 
and presentation, in the treated samples compare to the control samples. Even though these 
treated samples overexpress similar genes and pathways compare to the control samples, a 
different in their gene expression profile was seen (Figure 11C). I examined more closely 
the expression of various immune suppressive markers in the different samples. The level 
of overexpression of these markers when using INFγ was greater than the levels of 
overexpression of the same markers when using TNF⍺, relative to control samples (Figure 
14). This could be explained by a possible delay in the time course of full activation of the 
TNF⍺ treated MSC, or a difference in the level of activation of these genes in the TNF⍺ 
treated samples.   
  Another potential source of variability when using MSC to suppress the immune 
system, is the culture time. Due to technical circumstances, the MSC are cultured in 
conditioned media for a period of 48 to 72 hours before these are used for research or 
therapy. This procedure raises the question of whether the activation period of these cells 
affects their function. Our transcriptomic results suggest the additional 24 hours incubation 
have little effect on the genes expression profile of the MSC, with only 34 genes being 
found to be significantly differentially expressed at an FDR lower than 0.05, suggesting 
the function of these cells remain the same from 48 to 72 hours. 
The third experiment in this chapter focused on the effect γMSC on the T cells 
transcriptomic profile, sequenced with scRNA-seq technology.  The results confirm the 
suppression of the T cell mitotic cycle upon exposure to γMSC, as seen in previous 
studies(123-126). Contrary to previous studies(111), INFγ treated MSC don’t seem to 
suppress the T cell activation. The expression of the cell markers CD4 and CD8A showed 
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an important decrease in the abundance of CD4+ T cells in the treated samples compare to 
control sample, suggesting the γMSC promote differentiation of T-cells away from the 
CD4 helper profile toward the more cytotoxic CD8 state.  
For the four chapter of this thesis, I analyzed the single cell gene expression profile 
of bone marrow aspirates, currently use as treatments for osteoarthritis. As mentioned 
before, there are different sources of variability that can have an impact on the cell’s gene 
expression profile and thus in the patient’s outcome. In this case, I compare the content and 
gene expression profile of 21 BMAC samples from osteoarthritic patients and 25 sample 
from non-osteoarthritic donors.   
My preliminary analysis shows that the main source of variability in the BMAC gene 
expression profiles, beside the cell types variability, is due to the cell type variability, 
follow by the donor (sample) variability (Figure 21B). Sex, BMI and age seem to have a 
lower effect on the transcriptomics profile. The differential expression analysis further 
shows significant differences on the gene expression profiles of the cell types present in 
the BMAC related to the presence or absence of osteoarthritis, showing a higher activity 
of immune related functions such as TCR signaling, BCR signaling and T cell activation 
(Figure 22).  
Since Previous studies have demonstrated the involvement of the immune system  on 
the progression of the OA through the secretion of catabolic cytokines (144, 145) it is 
important to assess the activity of the immune system cells on the BMAC samples. These 
results suggest it may be helpful to consider the use of BMAC form healthy donors as 
treatment for osteoarthritis.   
 78 
In summary, this thesis shows transcriptomic analysis are useful to assess the difference 
in single cells and whole tissues, gene expression profiles. We could prove there are 
multiple sources of variability when using cells as possible treatments for different 
diseases. These sources of variability can be related to donor itself, his health condition or 
tissue of origin, and should be taking into account previous to their clinical use. A deeper 
characterization of these cells needs to be done in order to have more concise results during 
the clinical trials and a better understanding of their role in the patient’s outcome. 
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Figure S1: Heatmap displaying the top 50 DE genes for the between post-thaw and pre-freeze MSC 
comparison. The DEG analysis between these samples shows a significant overexpression of 1,743 genes on 
the pre-freeze samples, compared to 310 genes significantly overexpressed in the post-thaw samples. The 
most significant overexpressed pathways on the Pre-freeze samples are cell proliferation and cell adhesion, 
























































                               
 
 
Figure S2: PCAs created with Seurat (A) Two major clusters differentiate along PC1. These clusters 
correspond to the low (left) and high (right) UMI count cells. (B) This PCA shows the clusters BM-High_a 
and BM-High_b. This cluster are not as well differentiated when using Seurat as they are when clustering the 
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Figure S3: Dot plot displaying the MSC identity markers established by the ISCT. The size of the dots 
corresponds to the percentage of cells, in the tissue, expressing the gene. The color corresponds to the average 
non-zero expression of the gene, per cell, in each tissue. Light purple represents low expression per cell, 

























































































Figure S4: Dot plots displaying the top 16 differentially expressed genes in each group. The first 8 genes are 
overexpressed in BM derived MSC while the last 8 genes are overexpressed in UCT derived MSCs. 
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Figure S5: Dot plot displaying the average expression for cell adhesion and migration and 
immunomodulatory function-associated genes. The colors represent the average expression of the genes per 
cell. The scale is from low expression of 0 (gray) to high expression of 1.5 log counts per million (blue). The 
size of the dots represents the proportion of cells in each cluster that express the gene.
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Figure S6: Dot plots displaying genes of interest. (A) This dot plot shows some pluripotent markers. (B) This 
dot plot displays stemness markers. The expression of some of these genes is low. There is not significant 
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Figure S7: Differential expression analysis between BM-High_a and BM-High_b using scPool with different 
pseudocells sizes. (A) This table shows the number of significant differentially expressed genes found with 
scPool using pool sizes of 10, 20 and 30 cells. (B) This plot displays the log fold change of the significant 
differentially expressed genes found with a pool size of 10 compare to the significant differentially expressed 
genes found with a pool size of 20. (C) This plot displays the log fold change of the significant differentially 
expressed genes found with a pool size of 10 compare to the significant differentially expressed genes found 
with a pool size of 30. (D) This plot displays the log fold change of the significant differentially expressed 
genes found with a pool size of 20 compare to the significant differentially expressed genes found with a 
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Figure S8: Differential expression analysis between UCT-High_a and UCT-High_b using scPool with 
different pseudocells sizes. (A) This table shows the number of significant differentially expressed genes 
found with scPool using pool sizes of 10, 20 and 30 cells. (B) This plot displays the log fold change of the 
significant differentially expressed genes found with a pool size of 10 compare to the significant differentially 
expressed genes found with a pool size of 20. (C) This plot displays the log fold change of the significant 
differentially expressed genes found with a pool size of 10 compare to the significant differentially expressed 
genes found with a pool size of 30. (D) This plot displays the log fold change of the significant differentially 
expressed genes found with a pool size of 20 compare to the significant differentially expressed genes found 
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Figure S9: MA plot of the differentially expressed genes between BM-High_a and BM-High_b. The 
significant differentially expressed genes found using scPool, with a pool size of 20, and the Wilcoxon rank 
test in Seurat, are colored in red. In grey are the significant differentially expressed genes found with scPool, 
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Figure S10. One-way anova on the cell ration of the cell types depending on the KL score. A significant 

















































Figure S11. One-way anova on the cell ratio of the cell types depending on the sex. A significant difference 
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